MARTE BJERKREIM FURNÉE
SUPERVISOR: HANNE RØLAND HAGLAND

Lifestyle, Immune System and Their Role in Gut Microbiota and Colorectal Cancer

Bachelor, 2024

B-BIOKJE

Faculty of Science and Technology

Department of Chemistry, Bioscience and Environmental Engineering

Student Number: 260871

Number of Pages: 86

Abstract

Colorectal cancer (CRC) is a disease with a substantial public health challenge, originating in the colon or rectum, both crucial components of the digestive system. The development of CRC is influenced by a range of factors, including genetics, lifestyle choices, and environmental exposures to mutagens or carcinogens. Recent attention has turned to the gut microbiota, the diverse community of microorganisms in the human gut, and their association with colorectal cancer. This emerging field explores the intricate relationship between the gut microbiota, immune responses, and the entire spectrum of colorectal cancer, from initiation to treatment. Since the microbiota either can facilitate or hinder cancer development, it is becoming a promising avenue for innovative prevention and treatment approaches in fields of oncology and gastrointestinal health.

The composition and diversity of the human gut microbiota are shaped by various factors, with lifestyle choices exerting a notable influence. Nutrition, exercise, and environmental exposures are primary determinants impacting the gut microbiota. Dietary habits, particularly those rich in fiber, fruits, and vegetables, foster beneficial bacteria, promoting a diverse and balanced microbiome. Conversely, diets high in processed foods, sugar, and saturated fats may alter microbial composition, potentially contributing to health issues such as obesity, type 2 diabetes, and inflammatory diseases.

Regular physical activity emerges as another influential factor, with active individuals displaying a more diverse and beneficial microbial profile. Exercise is linked to a decrease in harmful bacteria and an increase in microbes supporting metabolic health, underscoring the positive impact of physical activity on gut microbiota composition. Environmental factors, including exposure to pollutants, pesticides, and antibiotics, can disrupt the delicate balance of the gut microbiota. Antibiotic use, for instance, may significantly reduce microbial diversity, heightening susceptibility to various health problems. Exposure to pollutants and pesticides may similarly alter the gut microbiota, potentially contributing to chronic diseases.

In summary, lifestyle choices encompassing dietary preferences, physical activity levels, and environmental exposures play a pivotal role in shaping the composition and function of the gut microbiota. This thesis aims to provide a comprehensive understanding of these connections, crucial for developing strategies to promote a healthy gut microbiome with positive implications for overall health and well-being.

Table of Contents

1. Introduction

Colorectal cancer (CRC), also known as bowel cancer, is a type of cancer originating in the colon or rectum. These components of the gastrointestinal tract are important in the digestion process, by absorbing nutrients and eliminating waste (1). CRC stands as one of the most prevalent forms of cancer globally, with the gut microbiome playing a fundamental role in its genesis (2). The progression of colorectal tumors typically involves a multifaceted process characterized by histological, morphological, and genetic transformations. Early screening proves invaluable in identifying precancerous polyps among individuals at an average risk of developing colorectal cancer, potentially reducing the likelihood of metastasis (3). Despite the merits of early screening, colorectal cancer continues to be the second leading cause of cancer-related deaths in the United States (4). The incidence of colorectal cancer in Norway has tripled during the past 60 years, leading to the second most common type of cancer, with more than 4000 new cases every year (5). Therefore, healthcare providers need a comprehensive understanding of colorectal cancer risk factors and the stages of disease development to recommend effective screening approaches.

The gut microbiome is composed of trillions of microorganisms and resides in the gastrointestinal tract, playing a crucial role in maintaining digestive health, immune function, and metabolism. Emerging research suggests an association between the gut microbiome and development of colorectal cancer, highlighting the importance of having a healthy gut with diverse gut bacteria (6). Alterations in the composition and diversity of bacteria in the gut, termed dysbiosis, are associated to the initiation and progression of CRC (7). There are several beneficial bacteria residing the gut microbiome, modulating the immune responses, and maintaining homeostasis. Conversely, certain bacteria may produce carcinogenic metabolites, inducing inflammation that may be chronic, or compromise the integrity of the gut barrier, contributing to tumorigenesis (8). The gut microbiome and its role in the development of colorectal cancer is an interesting field and holds promise for future therapeutic interventions and diagnostic strategies.

The reason why early detection and intervention is important for successful treatment is because the development of malignant polyps and colorectal cancer spans several years (9). Embracing a healthy lifestyle, involving a balanced diet rich in fiber, engaging in regular physical activity, and abstaining from smoking and excessive alcohol consumption, can significantly contribute to lowering the risk of colorectal cancer. Comprehending the

complexities of colorectal cancer, encompassing the interplay of the gut microbiome, associated risk factors, and treatments, is important for effective management and prevention.

2. The Gastrointestinal Tract and Intestinal System

The human body consists of nearly 37 trillion of cells (10), each requiring continually supply of energy to sustain important processes, like cellular respiration, homeostasis and metabolism. The absorption of essential nutrients from the consumption of food is a complex process, involving several organs and physiological mechanisms. Nutrients encompass all the essential element the body requires, including vital organic substances like proteins, carbohydrates, and lipids. These organic compounds serve as energy sources, sustaining the energy-demanding processes within the human body (11). The digestive tract plays a crucial role in the breakdown of the large organic macromolecules into smaller compartments with important physiological functions.

The digestive system comprises two primary components: the gastrointestinal tract (GI-tract) and accessory organs (12). The GI-tract has essential roles such as digesting and absorbing nutrients, as well as participating in the secretion of substances and immune responses. The GI-tract consists of the mouth, esophagus, stomach, small intestine, large intestine (colon), rectum, and anus, while the liver, gallbladder, pancreas, and salivary glands are accessory organs (12), aiming the digestion process by secreting various fluids and enzymes (Figure 2.1).

The GI-tract is a continuous chain of organs responsible for the entry of food at one end and the expulsion of waste at the other (13). Smooth muscles line these organs, generating rhythmic contractions known as *peristalsis*, a wave-like motion which propels food down the GI-tract (14). Within the digestive tract, large nutrient molecules like proteins, carbohydrates and fat undergo the process of breaking down into smaller molecules, facilitating their transportation into the bloodstream or lymphatic vessels (15). Proteins are broken down into amino acids, which are crucial for diverse cellular functions like signal transduction, nutrient transport, and maintenance of cellular structure. Carbohydrates, like sugar and starch, are metabolized into glucose, while fat molecules are converted into fatty acids and glycerol.



***Figure 2.1**. Structure of the gastrointestinal tract and accessory organs (16).*

The walls of the GI-tract are divided into four layers (Figure 2.2). From the lumen outward:

Mucosa

Mucosa is the innermost layer of the GI-tract, facing the intestinal lumen and is in directly contact with the contents of the GI-tract. Mucosa is composed of an epithelial layer, a connective tissue layer and a thin layer of smooth muscle. The epithelial layer consists of epithelial cells facing the intestinal lumen. The connective tissue layer is called *lamina propria*, containing blood vessels, lymphatic vessels, and various immune cells. The lamina propria serves as a barrier, preventing the passage of microorganisms that could otherwise breach the epithelial layer and enter the bloodstream. Moreover, lymph nodes play a crucial role in inhibiting microbial infiltration. The thin layer of smooth muscle, called muscularis mucosae, helps the movement and folding of the mucosa. Additionally, the mucosa layer consists of invaginations called intestinal glands (colonic crypts), lined with cells specialized in absorption of nutrients and other substances (17).

Submucosa

Submucosa is a thick layer, providing support to the mucosal layer. Submucosa is important for nutrient absorptions since it contains blood vessels and lymphatics transporting absorbed nutrients away. Additionally, the submucosa contains nerve endings that form the *submucosal*

plexus, contributing to the control of various physiological functions within the digestive system (17).

Muscularis Externa

The muscularis externa consists of two primary smooth muscle layers: an inner circular layer and an outer longitudinal muscular layer. The myenteric (Auerbach) plexus is situated between these two layers. The myenteric plexus orchestrates the synchronized contraction of the muscular layers, thereby regulating peristalsis. The thickness of the muscularis externa varies across different segments of the GI-tract. For example, due to the presence of large and heavy fecal matter, necessitating increased force for propulsion forward, the muscularis externa is notably thicker in the colon (17).

Serosa and Adventitia

The outermost layer of the gastrointestinal tract is either serosa or adventitia and contains several layers of connective tissue. Both serosa and adventitia contain blood vessels, nerves, and lymphatics (17). Serosa is a thin layer containing a double wall of simple squamous epithelium (mesothelium). Serosa is a smooth membrane consisting of a thin layer of connective tissue and cells responsible for producing serous fluid, which serves to lubricate internal structures and minimize friction during movement (18). While serosa covers intraperitoneal structures and is continuous with the parietal peritoneum, adventitia covers retroperitoneal structures and is made of fibrous connective tissue (18). Securing structures together is the primary function of adventitia, rather than reducing friction between them.



***Figure 2.2**. Layers of the gastrointestinal tract. Mucosa is the innermost layer facing the intestinal lumen, while serosa is the outermost layer (19).*

The stomach is surrounded by serosa since most of the stomach is intraperitoneal. Conversely, the pylorus of the stomach is retroperitoneal and consists of a fibrous adventitia holding it in place (18). Most of the small intestine is also intraperitoneal, consisting of a thin layer of serosa secreting a serous fluid. The serous fluid reduces the friction from the movement of the muscularis propria layer. Conversely, the first section of the duodenum is retroperitoneal and has adventitia instead. The intraperitoneal parts of the colon, including the caecum, appendix, transverse colon, sigmoid colon, and rectum, consists of serosa. Meanwhile the retroperitoneal parts of the colon, including the ascending and descending colon, as well as the anal canal are covered by adventitia. The intraperitoneal segments of the colon require the fluid secreted from the serosa to reduce friction, while the more fibrous adventitia of the retroperitoneal segments of the colon serves to keep these parts in place (18).

2.1 The Oral cavity, Pharynx, and Esophagus

Obtaining nutrition and energy from food involves a multi-step process, including ingestion, digestion, absorption, and elimination. Ingestion is the first step and refers to the intake of food process through the oral cavity (mouth), with the teeth facilitating the mechanical breakdown of food into smaller fragments (15). The mechanical breakdown enhances both the surface area available for chemical breakdown and the act of swallowing (20). In addition to mechanical breakdown, salivary glands produce *salvia* consisting of enzymes that facilitates the chemical breakdown of food. *Amylase*, an enzyme present in salvia, breaks down starch (a plant-derived glucose polymer) and glycogen (an animal-derived glucose polymer) into maltose (21). Moreover, maltose undergoes further processing into two glucose molecules in the small intestine where most of the chemical breakdown occurs (20). Salvia also contains mucus, serving to lubricate food for smoother swallowing, shield the gums against abrasion, and contribute to the senses of taste and smell. The synergistic action of these processes transforms the food from large particles into a soft mass, called bolus, which is directed to the *pharynx* (throat region), leading to two different pathways: the *esophagus* and the *trachea* (Figure 2.3). The esophagus, a muscular tube connecting to the stomach, is responsible for the smooth transit of food, while the trachea (windpipe) leads to the lungs. Swallowing requires precise coordination to prevent food and liquids from entering the trachea, avoiding the risk of choking or tracheal blockage. Within the esophagus, peristalsis, characterized by alternating waves of smooth muscle contraction and relaxation, propels food along its journey (22).



***Figure 2.3**. Intersection of the human airway and digestive tract (22).*

2.2 Digestion in the Stomach

The stomach is situated below the diaphragm and has two different roles in the digestive process. Firstly, it serves as a storage facility. The elastic wall of the stomach allows it to expand and accommodate approximately 2 litres of food and fluid. The second function of the stomach involves the transformation of food into a liquid suspension. The stomach secretes gastric juice, a digestive fluid, which blends with the ingested food through a churning action, resulting in a mixture called chyme (22).

The stomach secretes two types of gastric juice: *hydrochloric acid* (HCl) and *pepsin* (23). The production of HCl by gastric parietal cells is responsible for creating the highly acidic environment within the gastric lumen (pH<2) (24), potent enough to eliminate most bacteria from ingested food and supports the absorption of essential minerals like phosphate, calcium, and iron (24). Because of the low pH, proteins are denatured, exposing the peptide bonds. Pepsin is a protease enzyme specialized to function optimally in an acidic environment (25). It serves as a protein-digesting enzyme, catalyzing the hydrolysis of peptide bonds within proteins, breaking proteins down into amino acids.

The muscular activity of the stomach is characterized by coordinated contractions and relaxations; a process known as churning. Churning enhances chemical digestion by ensuring contact between all the food and gastric juices, resulting in a nutrient-rich chyme. Peristaltic contractions facilitate the movement of stomach contents into the small intestine within 2-6 hours post-meal. The *sphincter* located at the bottom of the stomach regulates the passage of chyme into the small intestine (22).

2.3 Digestion and Absorption in the Small Intestine

The small intestine is the primary site for enzymatic hydrolysis of macromolecules from food, where absorbed nutrients enter the bloodstream which transports the absorbed nutrients to the rest of the body (22). Chyme progresses at a slower pace within the small intestine, allowing for comprehensive digestion and absorption. The deceleration is facilitated by segmentation contractions performed by the circular muscles in the intestinal walls. The segmentation contractions move chyme in both directions, promoting better mixing with digestive juices and extending the contact time with the intestinal walls (22). The small intestine measures over 6 meters in humans and consists of *duodenum*, *jejunum,* and *ileum* (Figure 2.4). The duodenum, which encompasses the first 25 cm of the small intestine, receives bile from the liver (26). Bile, which is stored in the gallbladder, emulsifies fats, facilitating the breakdown by lipases into fatty acids, glycerol and monoglycerides. Pancreatic juice from the pancreas, containing proteases, lipases, and amylase, plays a crucial role in protein and fat digestion. The small intestine also manufactures its own enzymes for carbohydrate hydrolysis, including peptidases, sucrase, lactase, and maltase. Hormones released by the stomach and duodenum regulate the secretion of digestive fluids into the alimentary canal. The epithelial lining of the duodenum contributes additional digestive enzymes, with some being released into the duodenal lumen and others binding to the surface of epithelial cells. The additional digestive enzymes from the epithelial lining of the duodenum, along with pancreatic enzymes, complete most of the digestion in the duodenum (22).

The contents of the duodenum progress through peristalsis into the jejunum and ileum, the remaining sections of the small intestine (22). The intestinal lining features large folds studded with finger-shaped projections known as *villi* (17). Within these villi, each epithelial cell has many microscopic projections called *microvilli,* oriented toward the intestinal lumen. This intricate combination of folds, villi, and microvilli results in an extensive surface area of 200-300 m^2, an evolutionary adaptation significantly enhancing nutrient absorption rates (22) (Figure 2.4).



***Figure 2.4**. Structure of the small intestine. The folded mucous membrane of the small intestine is covered with projections called villi and microvilli. These structures significantly enhance the absorption surface area. Absorbed nutrients are transported into circulation through blood capillaries and lymph channels (27).*

Transport across the epithelial cells can either be passive or active, depending on the type of nutrient (22). For instance, fructose undergoes facilitated diffusion down its concentration gradient from the small intestine lumen into epithelial cells. Subsequently, fructose exits the basal surface and enters microscopic blood vessels (capillaries) at the core of each villus for absorption. In contrast, amino acids, small peptides, vitamins, and most glucose molecules are actively transported against concentration gradients into the epithelial cells of the villus. This active transport mechanism enables more efficient nutrient absorption compared to relying only on passive diffusion.

The capillaries and veins transporting nutrient-rich blood from the villi converge into the *hepatic portal vein*, a blood vessel directing blood straight to the liver. Afterwards, the blood flows from the liver to the heart and other tissues and organs. This arrangement enables the liver to regulate the distribution of nutrients throughout the body. Since the liver converts many organic nutrients into different forms for utilization elsewhere, the nutrient balance of the blood leaving the liver may significantly differ from the blood that entered. Additionally, the liver is the primary site of detoxifying drugs and certain metabolic waste products that are foreign to the body, and the arrangement allows the liver to remove toxic substances before circulation (22).

While water-soluble nutrients such as amino acids and sugars leaving the small intestine by entering the bloodstream to further processing in the liver, some products of fat digestion (triglycerides, or triacylglycerol) follow a different route. Hydrolysis of fat by lipase in the small intestine produces fatty acids and a monoglyceride (glycerol joined to a fatty acid). These products are absorbed by epithelial cells and reassembled into triglycerides. The triglycerides are forming water-soluble globules called chylomicrons. The chylomicrons exit the small intestine through narrow vessels called lacteals and later transferred to the blood through large veins leading to the liver and heart (22).

In addition to nutrient absorption, the small intestine is also important in the recovering of water and ions. Each person consumes approximately 2 L water and secretes approximately 7L in digestive juices into the alimentary canal. However, almost all the water is absorbed in the intestines through osmosis when sodium and other ions are actively pumped out of the intestinal lumen (22).

2.4 Processing in the Large Intestine

The alimentary canal concludes with the large intestine, encompassing the *colon*, *caecum*, and *rectum* (Figure 2.5). The small intestine connects to the large intestine at a T-shaped junction, with one arm leading to the 1.5-meter-long colon, ultimately reaching the rectum and anus. The other arm forms a pouch known as the caecum, crucial for fermenting ingested material, especially in animals consuming substantial amounts of plant matter. In comparison to many other mammals, humans possess a relatively small caecum. The human caecum extends into the *appendix*, a finger-shaped extension believed to function as a reservoir for symbiotic microorganisms (22).

Since most of the chemical digestion of nutrients and absorption processes take place in the small intestine, the nutrient contents significantly decrease as the contents of the small intestine move into the large intestine. The large intestine lacks the presence of villi and microvilli, resulting in a substantially reduced surface area that is less effective for absorbing large volumes of nutrients. Nevertheless, the colon plays an important role in completing the water recovery process initiated in the small intestine, along with the absorption of salts. The abundance of mucus-producing cells in the large intestine serves to lubricate the intestinal contents, facilitating their smooth transit through the intestine despite the predominant water absorption. The residual material, termed feces at this point, represents the waste of

the digestive system, and undergoes a gradual solidification as peristalsis propels it along the colon. Colon bacteria, known as the gut microbiome, break down indigestible substances through fermentation, producing absorbable vitamins. The terminal segment of the large intestine is the rectum, where feces are stored until elimination occurs (22).



***Figure 2.5**. Structure of the large intestine, comprising the colon, cecum, and sigmoid colon (28).*

2.5 Introduction to Microbiome and Microbiota

The human body hosts over a hundred trillion microorganisms, including bacteria, viruses, fungi, and protozoa, inhabiting various parts of the body such as the skin, lungs, eyes, and ears, with a significant concentration located in the gastrointestinal tract (29). The specific microorganisms residing in a specific environment, such as the gastrointestinal tract, is usually referred to as a microbiota. On the other hand, a microbiome refers to the genetic material of all the microorganisms, both symbiotic and pathogenic, in the microbiota, determining the behavior of these microorganisms (30). Microbiomes are unique to each organism, and the diversity among individuals can be substantial. Specifically, the gut microbiome encompasses the combined genetic material of microbes residing in the gastrointestinal tract, including bacteria, archaea, viruses, and fungi. Among adults, some of the most commonly encountered

or acknowledged genera of gut bacteria are *Bifidobacterium*, *Lactobacillus*, *Bacteroides*, *Clostridium*, *Escherichia*, *Streptococcus* and *Ruminococcus* (31). Different microbiomes in humans can impact health outcomes by influencing nutrition, immunity, behavior, and development of diseases.

The role of microbiomes in sustaining health of living systems is a subject of ongoing exploration (32). Generally, the microorganisms present in the gut microbiome do not induce infections or inflammation. In fact, most of these microorganisms have positive effects on the overall health. For instance, the microorganisms in the gut microbiome compete with pathogens for space and nutrients, produce essential vitamins like Vitamin K, generate nutrients for intestinal epithelial cells (IEC), stimulates the development of the immune system and lymphoid tissue, and develop immunological memory (33). Additionally, the human gut microbiome plays a crucial role in digestion and nutrition, with emerging evidence suggesting potential connections to certain cancers and influences on brain processes and mental health. Certain bacteria within the gut microbiome play crucial roles in the digestion process of food components that humans cannot digest on their own. However, alterations in the composition of the gut microbiome, known as dysbiosis, have been linked to gastrointestinal disorders such as inflammatory bowel disease (IBD) and colorectal cancer (34).

2.6 Lifestyle Diseases

Having a healthy lifestyle not only improves life quality but also reduces the likelihood of developing multiple lifestyle diseases. Lifestyle diseases includes a range of health issues largely influenced by individual lifestyle choices and behaviors. These disorders include conditions such as cardiovascular diseases, type-2 diabetes, obesity, certain forms of cancer, and chronic respiratory diseases (35). There is growing evidence that the condition of the gut microbiome significantly impacts human health and the overall well-being. Therefore, an understanding of the composition of microorganisms located in the gut microbiome is an important field of research (36). Although most of the bacteria residing the gut microbiome are benign or beneficial, some gut microbes produce toxic compounds. Immune defense mechanisms within the GI-tract, such as the mucus barrier, are crucial in the protection of tissues from potential damage caused by harmful bacteria.

A diverse and healthy microbiota performs vital functions including facilitating digestion, enhancing nutrient absorption, fighting off harmful bacteria, metabolizing toxins, and

synthesizing essential vitamins such as folate, vitamin B2, vitamin B12, and vitamin K. Since 80% of the immune system resides in the gut, gut health is important in influencing the immune system (37). The gut is intricately connected to the brain and nervous system, contributing to improved mental health by reducing inflammation and regulating the production of neurotransmitters, including serotonin (38). An overgrowth of harmful bacteria and a decline in beneficial bacteria have therefore been associated with various health conditions such as irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), obesity, metabolic disorders like diabetes, autoimmune disorders, allergies, depression, and anxiety (39).

Lifestyle-related factors have also been associated with the development of colorectal cancer (CRC). Indeed, over 50% of all colorectal cancers are associated with modifiable risk factors like obesity, physical inactivity, tobacco, alcohol and lifestyle diseases like diabetes (40). Studies have shown that people with an active lifestyle have a 25% lower risk of developing CRC, while people with an inactive lifestyle face up to a 50% higher risk(41). Obesity can promote carcinogenesis disrupting the gut microbiome, promoting irritation and inflammation of the epithelium of the large intestine. Because of the inflammatory characteristics of adipose tissue, obesity can promote the onset of cancer beyond the digestive tract by releasing tumor-promoting cytokines into the bloodstream. Additionally, excess body weight increases the release of mutagenic free oxygen radicans because of the disruptions of metabolic processes (42).

There is a higher rate of colon cancer in African Americans than in rural South Africans (43). In a recent study from 2015 (43), researchers conducted an experiment by replacing the traditional high-fiber diets of a group of rural South Africans with the high-fat, meat-heavy diets typically consumed by African Americans. After only two weeks on the high-fat, low-fiber diet, the rural African group demonstrated increased inflammation of the colon and a decrease in levels of butyrate, a short-chain fatty acid associated with reduced colon cancer risk. Conversely, the African Americans that transitioned to a high-fiber, low-fat diet experienced the opposite effect. The reduction in fiber intake led to diminished fuel for bacteria in the gut, resulting in a decline in the diversity among bacteria.

Different types of food have different impact on the composition of the gut microbiome and dietary choices play therefore a significant role in maintaining gut health. A diet abundant in fruits, vegetables, whole grains, and lean protein supports a healthy gut, while a diet high in

processed foods, sugar, and saturated fat can disturb the equilibrium of beneficial bacteria, leading to a condition called dysbiosis. Consequently, poor dietary choices lead to a decrease of essential bacteria in the gut, increasing the likelihood of inflammation and development of cancer. While red and processed meats increase the risk of CRC (44), other food components such as calcium, fiber, vitamin D, and fruit and vegetables have demonstrated a protective effect against CRC. Short-chain fatty acids are generated when bacteria metabolize fiber. These fatty acids nourish the gut barrier, enhancing immune function, while preventing inflammation, thereby reducing the risk of cancer (45). Moreover, other lifestyle factors like stress, exercise, and sleep also show an impact of the composition of the microbiome (46). While genes are unchangeable, improving the microbiome is possible, particularly through daily dietary choices.

3. The Innate and Adaptive Immune System

The immune system encompasses a complex network of cells, chemicals, and mechanisms with the purpose of protecting the human body against foreign pathogens like bacteria, fungi, parasites, viruses, cancer cells, and toxins. The immune system can be categorized into two main compartments: the innate immune system and the adaptive immune system. The innate immune system is a non-specific defence mechanism and serves as the initial defence against invading pathogens, with immune cells already present at the site of infection. Cells within the innate immune system express pattern-recognition receptors (PRRs) on the cell surface, including Toll-like receptors (TLRs) and NOD-like receptors (NLRs), which recognize pathogen-associated molecular patterns (PAMPs) originating from pathogens, as well as damage-associated molecular patterns (DAMPs). DAMPs are endogenous molecules released into the extracellular environment upon cellular damage, stress, or death. (47)

Hematopoietic stem cells (HSCs) differentiate into blood- and immune cells through a process called *hematopoiesis* (Figure 3.1). HSCs, found in the bone marrow, have the potential to differentiate into various types of immune cells (48). Immune cells of the innate immune system derive from a specialized precursor known as the *myeloid progenitor cell*, whereas immune cells of the adaptive immune system differentiate from the *lymphoid progenitor cell*. The innate immune system comprises macrophages, mast cells, granulocytes (such as neutrophils, eosinophils, and basophils), dendritic cells (DCs), and natural killer cells (NK-cells), while the adaptive immune system comprises lymphocytes. Despite originating from

lymphoid progenitor cells, NK-cells function as essential components of the innate immune system.



***Figure 3.1**. Schematic overview over the hematopoiesis, resulting in the immune cells of the innate and adaptive immune system (49).*

Innate immunity comprises barrier defense mechanisms and molecular recognition, wherein specific sets of receptor proteins bind to molecules or structures common to various viruses, bacteria, or pathogens. Activation of these receptors by foreign molecules triggers internal defenses, allowing responses to a wide array of pathogens. Mammalian barrier defenses, like the mucous membrane and skin, blocks the entry of many pathogens. The mucous membranes lining the digestive, respiratory, urinary, and reproductive tracts secrete mucus, a viscous fluid that traps pathogens and other particles. Pathogens in food, water, or ingested mucus also encounter the acidic environment of the stomach (pH 2), which kills most pathogens before they can reach the intestines (22).

The innate immune system is fully developed at birth, providing immediate protection against pathogens and other threats without the need for prior exposure. Conversely, the adaptive immune system is characterized by antigen-specific responses and relies on the recognition of specific antigens (50). The adaptive immune system takes longer to recognize infection, especially during the initial encounter of a new pathogen. Unlike innate immunity, the adaptive immune system improves over time as one is exposed to pathogens, because of the possibility of immunological memory. The immunological memory allows the adaptive

immune system to give a faster and more efficient response upon subsequent exposure to the same antigen.

Neutrophils and macrophages are two types of phagocytic cells in the mammalian body (22). Neutrophils are circulating in the blood and respond to signals from infected tissues, eliminate the pathogens through engulfing. Macrophages are larger phagocytic cells. Some macrophages migrate throughout the body, while others reside permanently in organs and tissues where pathogen encounters are likely. Two additional types of immune cells, dendritic cells, and eosinophils, also contribute to innate defense. Dendritic cells are abundant in environmental-contacting tissues like skin, initiating adaptive immunity after engulfing pathogens. Eosinophils, commonly located beneath epithelium, play a crucial role in defending against multicellular invaders such as helminths. Innate defenses in vertebrates also include natural killer (NK) cells, which circulate through the body detecting abnormal surface proteins on virus-infected or cancerous cells. NK cells release chemicals inducing cell death, inhibiting further virus or cancer spread. The lymphatic system is also a part of the cellular innate defense mechanisms in vertebrates and distributes lymph fluid throughout the body. Pathogens that enter from interstitial fluid are engulfed by some macrophages that reside in lymph nodes. Dendritic cells are usually located outside the lymphatic system. However, upon encountering pathogens, DCs migrate to lymph nodes and interacts with other immune cells, thereby stimulating adaptive immunity (22).

Immune cells play important roles in the protection against infections and maintaining homeostasis, which refers to the maintenance of internal stability and equilibrium despite external changes. Figure 3.2 gives a comprehensive comparison between the adaptive immune system and the innate system. It is important to note that the innate immune system and adaptive immune system work together in a complementary manner, with defects in either system can result in vulnerability or inappropriate immune responses (50). Usual, the immune system identifies cancer cells as foreign objects and initiates an attack, effectively eliminating tumors even before they reach a detectable size. However, some tumors manage to hide themselves from the immune system, thereby evading this protective mechanism. Understanding the function of the immune system provides insights into how the activity of different immune cells coordinates to recognize and eliminate cancer cells (51).



***Figure 3.2**. A comparison of the adaptive immune system and the innate immune system (52). Abbreviations: CLA: Cutaneous Lymphocyte-associated Antigen; TCR: T-cell receptor.*

3.1 Lymphocytes

The adaptive immune response relies on lymphocytes which originate from hematopoietic stem cells in the bone marrow and mature in primary lymphoid organs. Some lymphocytes migrate to the thymus, an organ located in the thoracic cavity above the heart, developing into T-lymphocytes. Lymphocytes that remain and mature in the bone marrow develops into B-lymphocytes. T-lymphocytes are referred to as T-cells, while B-lymphocytes are referred to as B-cells. B-cells undergo antigen-independent development, producing diverse B-cell antigen receptors (BCRs). T-cells undergo positive and negative selection in the thymus, yielding functional T-cells capable of distinguishing foreign antigens from autoantigens. Another type of lymphocyte, known as natural killer cells, remains in the blood and has an important role in innate immunity (53).

In adaptive immunity, an antigen, such as a protein from a bacterium or virus, binds to an antigen receptor on the cell surface of B-cells or T-cells. An antigen is any substance that provokes a B- or T-cell response, and the small, accessible part of an antigen that binds to the antigen receptor is called the epitope. Antigens are typically large foreign molecules, such as proteins and polysaccharides. A specific B-cell or T-cell produces antigen receptors that are identical, binding to the same epitope of an antigen. Every B- and T-cell has about 100,000 identical antigen receptors on the cell surface. All antigen receptors produced by a single B- or T-cell are identical and binds to the same epitope, enabling it to respond to any pathogen that produces molecules containing that epitope. The antigen receptors of B- and T-cells share similar components but encounter antigens through different mechanisms (22).

The B-cell antigen receptor contains four polypeptide chains: two identical heavy chains and two identical light chains. Disulfide bridges interconnect these chains, forming a Y-shaped protein (Figure 3.3) with two identical antigen-binding sites. Each light chain or heavy chain consists of a constant (C) region, called Fc-region (Fragment Crystallizable), consisting of amino acid sequences that vary little among receptors on different B-cells. Additionally, each heavy or light chain contains a variable (V) region, called Fag-region (Fragment Antigen Binding), where amino acid sequences vary broadly between B-cells (22).

Upon activation by interaction between an antigen and a B-cell antigen receptor, B-cells undergo clonal expansion, a process where B-cells proliferate to produce a large population of identical daughter cells with the same antigen specificity (idiotype). Activated B-cells can either differentiate into effector cells, also called plasma cells, or memory cells. Plasma cells produce and secrete antibodies, also called immunoglobulins (Ig) with the same specificity as the B-cell antigen receptor (BCRs). The secreted antibody also has the same structure as B-cell antigen receptors without the membrane anchor. By secreting B-cell antigen receptors as antibodies into the extracellular matrix, the antibodies promote a directly defense mechanisms against pathogens in body fluids (22).

Activated B-cells can undergo class switching (isotype), a process where the class of antibodies produced change, while maintaining the same antigen specificity. The variations among the amino acid sequences of the variable regions yield diverse binding surfaces, enabling highly specific binding. There exists five classes of antibody classes: IgM, IgD, IgG, IgE and IgA, with IgA playing a crucial role in the mucosal immune system (54). Without class switching, all antibodies would be of the IgM class, because the gene coding for IgM is located first in the

genome. Given that IgM not always provide the best defence against a specific pathogen, class switching is crucial for provoking an appropriate and effective immune response against the threat. Intact antigens present in the blood or lymph are recognized by both B-cell antigen receptors and antibodies.

The antigen receptor on the cell surface of T-cells contains two distinct polypeptide chains: an α-chain and a β-chain, connected by a disulfide bridge (55). The transmembrane region near the base of the T-cell antigen receptor secures the molecule within the plasma membrane of the cell. The variable regions of the α-chain and β-chain forms a singular antigen-binding site, while the remaining portions consist of constant regions. T-cell antigen receptors recognize antigens only when presented in association with major histocompatibility complex (MHC) molecules on the surface of antigen-presenting cells (APCs) or target cells. APCs include dendritic cells, macrophages, and B-cells (55).

Because B-cell antigen receptors are released extracellularly as antibodies by plasma cells, the two antigen-binding sites increases the chance of binding to a pathogen (56). On the other hand, T-cell antigen receptors (TCRs) do not undergo somatic hypermutations or class switching, and remain bound to the cell membrane, surrounded by thousands of other TCRs with the same antigen specificity.



***Figure 3.3**. Structure of a B-cell antigen receptor (BCR) and a T-cell antigen receptor (TCR) (57).*

Activation of Naïve B- and T-lymphocytes

B-cells can recognize a wide range of pathogens independently, without activation from T-cells. However, B-cells can only undergo somatic hypermutation, class switching, and develop immunological memory through T-cell mediated activation (Figure 3.4). T-cell mediated activation of naïve B-cells requires two signals. The initial signal occurs when the BCR binds to a foreign antigen, followed by the second signal, where CD40 on the surface of the B-cell binds to CD40L on the surface of a T-cell. Both the T-cell and the B-cell have the same specificity, meaning that the TCR recognizes the same pathogen as the BCR. Before the T-cell provides the CD40L signal to the B cell, a Th-cell has already been activated by an antigen-presenting cell. The activated T-cell produces cytokines that stimulate the B-cell. CD40L and the cytokines contribute to providing survival signals to the B-cell (56).



***Figure 3.4**. T-cell mediated activation of a B-cell (58). The first signal occurs when an antigen binds to the B-cell antigen receptor, while the second signal is facilitated by the interaction between CD40-CD40L, which involves a Th-cell that is already been activated by a dendritic cell presenting the same antigen.*

In contrast, T-cells cannot recognize an antigen unless the antigen is presented by antigen-presenting cells (APCs) (Figure 3.5). TCRs are never released extracellularly, which makes T-cells important for identifying intracellular pathogens. Cytotoxic T-cells (CTLs), T helper cells (Th-cells), and regulatory T-cells (Tregs) are the three main categories of T-cells (59). CTLs express the co-receptor CD8, while Th-cells and Tregs express the co-receptor CD4. There are two main types of regulatory T cells: natural CD4+ regulatory T cells (nTreg) and inducible CD4+ regulatory T cells (iTreg). T-cells become nTregs in the thymus, while iTregs become regulatory in secondary lymphoid organs (60). CTLs share many characteristics with NK-cells, which are part of the innate immune system. Both NK-cells and CTLs can target and eliminate host cells, but only if they are infected with a virus or transformed into cancer cells (61). This

elimination process occurs through mechanisms such as the Fas-FasL pathway or perforin-granzyme B pathway, ultimately inducing apoptosis in the target cell. While a single NK-cell can identify multiple pathogens, a single CTL typically recognizes only one specific pathogen.

Naïve T-cells recognize antigens through the MHC-antigen complex on APCs. There are two main classes of MHC (Major Histocompatibility Complex) molecules: MHCI and MHCII (Figure 3.5). All cells containing a nucleus express MHCI-molecules, while MHCII-molecules are only presented on the surface of APCs. MHCI-molecules and MHCII-molecules present different types of antigens. While MHCI presents endogenous antigens to CD8+ CTLs, MHCII presents exogenous antigens to CD4+ Th-cells and CD4+ Tregs. Endogenous proteins are proteins produced within the cells using the genetic information in the cell's DNA, while exogenous proteins are proteins that originate from external sources, such as proteins from pathogens (62).



***Figure 3.5**. A comparison between the structure of MHC class I and MHC class II (62).*

Activation of naïve T-cells involves two signals. The first signal occurs when the TCR complex, along with co-receptor CD4 or CD8, binds to the MHC/antigen complex, either MHCI/antigen or MHCII/antigen. Since CD4 and CD8 recognize the MHC-molecules presented by APCs, rather than directly binding to the pathogen antigen itself, the MHC-molecules do not need to be different on various T-cells. The second signal occurs when CD28 on the T cell binds to CD80/86 on the antigen-presenting cell (APC). CD28 and CD80/86 are identical on all T-cells and APCs. The interaction between CD28 and CD80/86 is crucial for initiating T-cell activation and clonal expansion, enabling signal transduction to transmit the activation signal into the cell nucleus (Figure 3.6) (63).



***Figure 3.6**. T-cell regulation by CD28 and CTLA-4 (64).*

During a viral infection, the virus uses the ribosomes of the host cell to synthesize new proteins (Figure 3.7). Some of these viral proteins are cleaved into peptides by proteases and transported into the endoplasmic reticulum (ER), binding to MHCI-molecules. The MHCI-peptide complex is transported to the cell membrane for recognition by CTLs. CTLs become activated and eliminate the infected cell if the viral antigens presented on MHCI are recognized as threats. Hence, this mechanism is crucial in immune defenses against viruses that attempt to evade detection within host cells. Moreover, the absence of MHCI molecules triggers the activation of NK-cells, which target and eliminate cells suspected of being virus-infected or cancerous (62).

Unlike MHCI, MHCII-molecules are only found on antigen-presenting cells (APCs) such as dendritic cells, macrophages, and B cells. APCs also express CD80/86 (also called B7), which is crucial for providing the second signal in T-cell activation (65). During phagocytosis, a cell engulfs exogenous proteins, which are broken down into peptide antigens within phagosomes. MHCII-molecules are transported within vesicles from the ER to the cytoplasm. The vesicles containing MHCII-molecules fuse with the phagosome, facilitating the binding of peptide antigens to MHCII. This MHCII-peptide complex is transported to the cell membrane for inspection from Th-cells and Tregs. The APCs presenting the exogenous antigen have already been activated; B-cells have undergone the first signal in the activation where BCR has bound to antigen, while macrophages and dendritic cells have been activated by PAMPs and/or DAMPs. An activated macrophage presents antigen to the already activated CD4+ Th-

cell (activated by dendritic cells in a lymph node), stimulating the macrophage by producing IFN-γ. The secretion of IFN-γ enhances the activity of the macrophage and the ability to break down pathogens in phagolysosomes.



***Figure 3.7**. MHC class I and MHC class II pathways (62). MHC class I present endogenous antigens to CD8+ T-cells, while MHC class II present exogenous antigens to CD4+ T-cells. Abbreviations: TAP: Transported Associated with Antigen Processing.*

Immunological Tolerance

Immunological tolerance is essential to prevent lymphocytes from initiating an immune response against autoantigens. Tolerance mechanisms can be divided into central and peripheral tolerance. Central tolerance refers to mechanisms occurring in primary lymphoid organs (bone marrow and thymus) during the maturation of lymphocytes. Peripheral tolerance refers to mechanisms outside primary lymphoid organs, preventing lymphocytes from reacting to autoantigens in peripheral tissues after maturation in the primary lymphoid organs. For T-cells, central tolerance occurs during maturation in the thymus. The outcome of central tolerance depends on the strength of T-cell binding to MHC and autoantigen. If a T cell fails to recognize MHC, it undergoes apoptosis in positive selection. Conversely, if T-cells bind strongly to autoantigens, they undergo apoptosis in negative selection. Therefore, central tolerance eliminates both non-functional T-cells incapable of activation due to failure to

recognize MHC and potentially harmful T-cells that may be autoreactive due to strong binding to autoantigens. As a result, central tolerance produces T-cells capable of recognizing foreign antigens on MHC (66).

Peripheral tolerance refers to regulatory mechanisms that reduce the risk of autoreactive lymphocytes initiating an immune response against autoantigens in peripheral tissues. The purpose of nTreg cells is to promote tolerance to autoantigens, while iTreg cells promote tolerance to harmless antigens, such as those from the microbiome. Peripheral tolerance aims to prevent autoreactive lymphocytes that have escaped central tolerance from causing harm (66).

3.2 Cytokines and Their Role in Immune Responses

Cytokines are small, signaling proteins serving as key regulators of both the innate and adaptive immune systems, facilitating cellular communication among immune cells through autocrine and paracrine pathways (67). Cytokines govern proliferation, differentiation, effector functions, and survival of immune cells. Some of the most important cytokines are interleukins (ILs), chemokines, transforming growth factors (TGFs), interferons (IFNs), and tumor necrosis factors (TNFs). Cytokines which promote inflammation are called pro-inflammatory, while cytokines that suppress the inflammatory process are called anti-inflammatory. IL-1, IL-2, IL-6, IL-21, and TNF-α are examples of pro-inflammatory cytokines which stimulate immune cells such as macrophages and neutrophils to enhance the inflammatory response. On the other hand, IL-10 and TGF-β are anti-inflammatory cytokines. Elevated levels of pro-inflammatory cytokines relative to the concentration of anti-inflammatory cytokines signify the presence of an ongoing infection and the necessity of an appropriate immune response (68).

Th-cells produce cytokines that stimulate the most efficient immune cells against the pathogen encountered. For instance, Th-cells produce cytokines that stimulate neutrophils during a bacterial infection, since neutrophils are effective against bacteria. A Th0-cell is a naïve Th-cell which has not yet been activated. Upon activation, the Th0-cell can differentiate into either "classical" T-helper cells called Th1, Th2 and Th17, follicular T-cells (Tfh) or inducible regulatory T-cells (iTregs) (Figure 3.8). Whether a Th0 cell differentiate into Th1, Th2, or Th17-cells depends upon signals received from dendritic cells and the cytokine environment produced by immune cells at the site of infection. Tfh-cells stimulate B-cells to undergo class

switching to produce antibodies best suited in the defense against the threat, while inducible regulatory T-cells suppress the immune response by secreting cytokines like IL-10 and TGF-β (69).

When Th0-cells are activated in an environment abundant in IL-12, Th0-cells differentiate into Th1-cells, initiating a *type-1 response*. The polarization towards Th1-cells occurs during infections involving intracellular pathogens such as viruses and some bacteria. Th1-cells produce pro-inflammatory cytokines like TNF-α and IFN-γ, which activates macrophages, NK-cells, and CD8+ CTLs. These immune cells are important in detecting and eliminating virally infected cells. IFN-γ, classified as a type II interferon, enhances NK-cells to detect virally infected cells, and stimulates macrophages. Moreover, IFN-γ inhibits the production of Th2-cells and Th17-cells, further promoting the polarization towards Th1 cells. Meanwhile, Tfh-cells, produced simultaneously with Th1 cells, stimulate B-cells to undergo class switching to IgG (65).

Th0-cells differentiate into Th2-cells in a *type-2-response* if the activation happens in an environment rich in IL-4. Three of the most important cytokines produced by Th2-cells are IL-4, IL-5, and IL-13, which stimulate eosinophils and basophils, essential in combating helminths. IL-13 stimulates the production of mucous in mucosal surfaces and increases peristalsis in the intestine. Tfh-cells stimulate B-cells to undergo class switching to IgE. IL-4 also inhibits the production of Th1 and Th17 cells, further promoting Th2 polarization. Th0-cells differentiate into Th17-cells in a *type-3-response* if Th0-cells are activated in an environment rich in IL-6 and TGF-beta. The type-3 response is important in the defense against extracellular bacteria and fungi. The most important cytokines produced by Th17-cells are IL-17, which stimulates neutrophils. Tfh-cells also stimulate class switching to IgG, which is the most effective antibody for opsonizing extracellular bacteria. IL-6 is a pro-inflammatory cytokine, while TGF-beta is an anti-inflammatory cytokine. If a Th0-cell is activated by TGF-beta without the presence of IL-6, it differentiates into inducible regulatory T cells (iTreg) (65).



***Figure 3.8**. Schematic overview of the major pathways of naïve CD4+ Th cell differentiation into effector cells (70).*

The production of pro-inflammatory cytokines indicates that innate immune cells have been activated by pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs), signaling danger (65). Occasionally, DCs may mistakenly present antigens on MHCII. These harmless antigens can be autoantigens or derived from harmless microorganisms in the microbiome. If a DC presents an antigen to a Th0-cell in an environment predominantly rich in TGF-β (an anti-inflammatory cytokine), the Th0-cell recognizes that the dendritic cell is presenting a harmless antigen. Instead of differentiating into effector cells, the Th0-cell differentiates into iTreg, which contributes to suppress the immune response (65). iTreg cells produce IL-10 and TGF-β, contributing to an anti-inflammatory environment. CTLA-4 is a protein found on iTregs, which binds to CD80/86 on DCs, preventing the second signal required for the activation of Th-cells and CTLs. iTreg cells promote tolerance to the microbiome, and become regulatory within secondary lymphoid organs, whereas nTreg cells become regulatory in the thymus. It is important to know that nTregs are intended to be autoreactive because upon activation, they create an anti-inflammatory environment and prevent activation of autoreactive Th-cells and CTLs. nTreg cells are not negatively selected in the thymus despite having autoreactive TCRs.

Interleukin 21

Cytokines have been investigated as potential treatments for cancer, given the capacity of the immune system to identify and eliminate cancer cells (Figure 3.9). A type of immunotherapy utilizes cytokines to address cancer and increases the cytokine concentrations in the body (67). The elevation of cytokine concentration serves to strengthen the immune system in two ways. The growth of T-cells accelerates, enhancing the ability to fight cancer cells, as well as the activation of other immune cells. Immunotherapy using cytokines are more general in their approach, whereas some newer treatments specifically target cancer cells. Interleukins and interferons are the most important cytokines produced for the defense against cancer cells. Typically, cytokine treatments are considered after exploring other treatment options.

IL-21 regulates both innate and adaptive immune responses and plays a significant role in promoting B-cell differentiation into plasma cells and in the generation of Tfh-cells. Additionally, IL-21 initiates a program within CD8+ CTLs that enhances their survival and increases their antiviral and antitumor activities (71). IL-21 has undergone assessment in phase I/II clinical trials as a monotherapy for melanoma, renal cell carcinoma, and metastatic colorectal cancer. A monoclonal antibody medical, called Cetuximab, used in treatments of certain cancer, was paired with IL-21 during phase I trials. This pairing demonstrated a 60% success rate in stabilizing stage IV colorectal cancer. However, the clinical study was stopped due to the discover of IL-21 involvements in chronic inflammatory bowel disease and the significant role in promoting the development of colon cancer through inflammation (67).



***Figure 3.9**. Interplay between immune cells, cytokines, and cancer cell death (72). Abbreviations: VEGF: Vascular endothelial growth factor; AG: antigen.*

4. Gut Microbiome Influence Colon Health

The gut microbiome comprises an estimated load of microorganisms ranging from 10^{13} to 10^{14}, representing over 1000 different bacterial species (73). The gut microbiome begins to development at birth and matures into a fully operational and stable microbiome within 2 to 3 years (74). Most of the bacterial special resides within the colon, which estimated to house approximately 70% of the human microbiome (2). The diverse community of the microorganisms lives together in a symbiotic relationship within the gastrointestinal tract in the human host. While genetic and environmental factors such as age, geographical location, alcohol or drug consumption, and dietary habits contribute to the individuality and variability of the intestinal microbiota over time, two main phyla, *Firmicutes* and *Bacteroidetes*, represent over 90% of all endogenous bacteria found in the gut microbiome of healthy adults. Other species found in the normal gut microbiome encompass *Eubacterium*, *Bifidobacterium*, *Fusobacterium*, *Lactobacilli*, *Enterococci*, *Streptococci*, and *Enterobacteriaceae* (73).

These microbial species in the gut microbiome carry out a range of functions, including the metabolism of indigestible food, modulation of the immune response, synthesis of nutrients. During digestion, food is converted into usable substances, including the absorption of glucose, an essential sugar to fuel both aerobic and anaerobic cellular respiration in all living organisms (75). While the digestive system acts as a factory, transforming food into fuel, the microbes serve as the essential workers. Therefore, the outcomes depend significantly on the quality of the inputs.

In healthy individuals, there is a dynamic interplay between the host and the microbes residing in the gut microbiome, maintaining a balanced environment within the gastrointestinal tract. However, any disturbance or disruptions of the gut microbiome, leading to an imbalance between beneficial and potentially pathogenic bacteria can contribute to various diseases due to the impact on metabolism and immune function. These changes are known as dysbiosis and can occur through alterations in Mus musculus miRNA (31). Dysbiosis is characterized by alterations in microbial patterns, functional composition, metabolic activities, or local distribution, disturbing the homeostasis in the gut microbiota.

Disruption of the gut microbiome has been related with a range of diseases including colorectal cancer, inflammatory bowel disease (IBD), diabetes, and metabolic syndrome (76). Factors such as antibiotic usage and specific dietary patterns have been implicated in the

development of dysbiosis (73). The imbalance in the gut microbiota can disrupt physiological functions through immune mechanisms, leading to inflammation and inflammatory diseases. Mechanisms include metabolic dysfunction, intestinal barrier impairment, and immune system disorders (77). For instance, changes in the intestinal microbiome may initiate and promote the development of colorectal cancer. *Fusobacterium nucleatum* is a gram-negative anaerobe and the most prevalent gut bacterium in CRC patients. Additionally, increased levels of *Fusobacterium nucleatum* often indicates a shorter overall survival, making it a prognostic biomarker. *Fusobacterium nucleatum* and *Escherichia coli* absorbs specific human sncRNA (small noncoding RNA), regulating the expression of microbial genes, influencing their growth. (2).

In eubiotic conditions (Figure 4.1 A), the microbiota plays a fundamental role in maintaining gut stability by producing short-chain fatty acids (SCFAs) such as acetate, propionate, and butyrate. In addition, the microbiota prevents the proliferation of microbial pathogens, and modulating the immune system, including the production of anti-inflammatory cytokines like IL-10 and TGF)-β, as well as reducing the activation of Th17 and Th1 cells. Conversely, during dysbiotic conditions (Figure 4.1 B) there is an overgrowth of bacteria from the Enterobacteriaceae family, resulting in reduced bacterial diversity and gut stability. There is a decrease in the production of SCFA and a simultaneous increase in pro-inflammatory cytokines such as IL-6, IL-17, and TNF-α, which activate Th17 and Th1 cells involved in the inflammatory response. Additionally, a decline in tight junctions and subsequent loss of the intestinal epithelial barrier integrity is observed.



***Figure 4.1**. Comparison of a normal, healthy intestine (A) with intestinal dysbiosis and inflammation (B) (78).*

4.1 The Defense Mechanisms of the Mucosal Immune System

The intestine is a continuous tubular structure responsible for most nutrient and water absorption within an organism (79), and represents the largest compartment of the immune system (80). The intestinal system is the port of entry of many clinically important pathogens, and is continually exposed to antigens and immunomodulatory agents from the diet and the commensal microbiota (80), and must respond appropriately based on tissue variations throughout the intestine. Interestingly, the entire intestine, including its lymph nodes, is considered an immunosuppressive organ compared to many other tissues. Although the acidic condition of the stomach (pH 2) neutralizes most of the microbes entering through ingestion, some manage to reach the intestine. The intestinal surface, characterized by villi that facilitate nutrient absorption, has the highest concentration of immune cells in the body. Consequently, maintaining a balance between tolerance towards food and commensal microbiota while recognizing pathogens has been an evolutionarily stable strategy (79). The immune response processes that occurs within the intestinal system are also increasingly involved in regulating the development of diseases in other parts of the body (81). The interaction between the gut microbiota and the intestinal epithelium is continuous and results in persistent immune signaling. Proper regulation of this immune response, along with maintaining epithelial barrier integrity and permeability in the presence of both commensal bacteria and invading pathogens, is crucial for preserving intestinal homeostasis. Disruption in this process can lead to infection or damage of the epithelial cells in the intestines, causing inflammation (37).

The intestinal mucosa is covered with a monolayer of epithelial cells and serves as the initial defense mechanisms against invasion of commensal bacteria or pathogens. The mucosal defense mechanism comprises the epithelial barrier and immunological barrier. While the epithelial barrier functions to prevent the systemic invasion of microbes through mechanisms such as tight junctions, mucus coating, and the secretion of antimicrobial peptides by intestinal epithelial cells (IECs), the immunological barrier relies largely on immunoglobulin A (IgA) antibodies. IgA antibodies prevents microbes from binding to IECs, inhibiting growth and virulence, and neutralize their toxins (82).

IgA acts as a monomer when circulating as an antibody in the blood but forms a dimer when secreted in mucosal secretions (Figure 4.2). IgA exists in both circulating IgA and secretory IgA forms (65). Plasma cells produce dimeric IgA in the lamina propria, targeting pathogens in the intestinal lumen. Dimeric IgA attaches to a receptor located on the basolateral side of

enterocytes. Through a mechanism known as transcytosis, the enterocyte takes up dimeric IgA and releases it into the intestinal lumen. The secretory component of IgA remains bound through transcytosis for preventing degradation of the stomach acid and proteases. IgA is a less potent antibody, deliberately designed to minimize immune response activation. This feature of IgA is advantageous in regions continually exposed to pathogens, where IgA binds to and neutralizes pathogens and toxins without triggering inflammation.



Figure 4.2. *(A) Schematic representation of IgA transcytosis from the lamina propria to the intestinal lumen through transcytosis. Dimeric IgA is recognized by polymeric immunoglobulin receptor (pIgR) on the basolateral side of the intestinal epithelial cells. (B) Protein components of secretory IgA, including the two IgA monomers, joining chain (JC), and the secretory component (SC). The heavy chain of IgA is colored white with a black outline, while the light chain is colored has a gray outline (83).*

The gut microbiota is crucial in facilitating the maturation of the human immune system and preserving immune system equilibrium within the intestine and beyond. Enteroendocrine cells (EECs) are recognized for their expression of Toll-like receptors (TLRs) and their initiation of NF-κB-mediated responses upon exposure to PAMPs. In response to the recognition of PAMPs, EECs produce and secrete pro-inflammatory cytokines and enteroendocrine peptides (EEPs). Additionally, the gut microbiota influences adaptive immune responses, specifically the development and differentiation of CD4+ and CD8+ T cells. B-cells are stimulated by Bifidobacterium, leading to the synthesizing and release of secretory immunoglobulin A (sIgA), which plays a significant role in the mucosal immune response. Both the direct activation of adaptive and innate immunity by the gut microbiota, and the indirect influence of metabolites derived from the microbiome on the immune response, are important in the maintenance of intestinal homeostasis (77).

The intestinal system employs several crucial defense mechanisms aimed against harmful bacteria, as well as maintaining homeostasis in the commensal microbiota. Certain cells, called goblet cells, secrete mucus, a viscous fluid enriched in mucin glycoproteins (Figure 4.3). Glycoproteins form large net-like structures, forming a protective barrier against microbes in the gut lumen, as well as providing lubrication to the epithelial surface. The secretion of mucus by goblet cells facilitates an upward flow within the crypts, effectively blocking bacterial infiltration (84). Additionally, goblet cells produce several important proteins like intestinal trefoil factor 3 (TFF3) and resistin-like molecule-β (RELMβ). RELMβ is a cytokine rich in cysteine which recruits CD4+ T-cells, thereby protecting against enteric pathogens. The recruited CD4+ T-cells produce IL-22, which is a cytokine that increases the proliferation of epithelial cells, contributing to the protective barrier. By forming goblet cell-associated antigen passages (GAPs), goblet cells induce adaptive immune responses, delivering the luminal substances to antigen-presenting cells (APCs) in the lamina propria. Hence, the functions of goblet cell are pivotal in both innate and adaptive immunity (84).



***Figure 4.3**. Overview of the immune regulation of goblet cell and production of mucin (85). Goblet cells are distributed throughout the gastrointestinal (GI) tract and synthesize and secrete mucins, thereby contributing to the production and maintenance of the protective mucus layer. Abbreviations: ILC2: Innate lymphoid cells group 2; TFF3: Trefoil factor 3.*

4.2 MALT, GALT, and Peyer's Patches

In addition to the innate and adaptive immune system, the mucosa-associated lymphoid tissue (MALT) serves as barrier against potentially harm substances found in the gastrointestinal tract (GI-tract) and maintaining mucosal immunity. MALT is an example of a secondary lymphoid organ, where lymphocytes are activated by antigens and develop into effector cells. Secondary lymphoid organs have specialized areas for B-cells and T-cells, where chemokines have important roles in the structural organization. Areas containing B-cells are called lymphoid follicles, which contain B-cells and follicular dendritic cells (FDCs). Unlike dendritic cells (DCs), FDCs facilitates B-cell activation by capturing antigens on the surface, enabling B-cells to have more time to recognize antigens. Additionally, spleen and lymph nodes are important secondary lymphoid organs. Gut-associated lymphoid tissue (GALT) is a component of MALT, serving as key sites for immune surveillance and defense against pathogens entering through mucosal routes (86).

The gut-associated lymphoid tissue (GALT) consists of a collection of multifollicular structures (87), and is one of the most diverse and complex immune compartments within the human body (88). Peyer's patches (PPs) and isolated lymphoid follicles (ILFs) are important structures of the GALT, having multifaced functions. Both PPs and isolated lymphoid follicles are covered with an epithelial monolayer known as the follicle-associated epithelium (FAE), containing microfold cells (M-cells). M-cells are specialized cells that collects antigen samples from the intestinal lumen (82). Figure 4.4 is an illustrative overview of the cellular composition of Peyer's patches. There is a high concentration of antigen-presenting cells located beneath the FAE, in the subepithelial dome (SED). Lymphocytes enter through high endothelial venules (HEV), forming a large concentration of B-cells located in B-cell follicles, as well as zones for T-cells. Interactions between T-cells and B-cells in these regions leads to the differentiation and expansion of B-cells, giving rise to the germinal center. In the germinal center, B-cells mature and produces plasma cells secreting antibodies of class IgA. The produced effector cells enter the circulation through mesenteric lymph nodes (MLNs), migrating to the lamina propria where plasma cells in the lamina propria generate dimeric IgA. Dimeric IgA are transported through the epithelium in a process called transcytosis. The secretory IgA can engage with the bacteria in the gut lumen (89).

Peyer's patches are a subtype of MALT situated in the small intestine, particularly concentrated in the ileum. Detection of harmful pathogens present in the intestinal tract are the primary function of the Peyer's patches. In addition, Peyer's patches are important in the initiation of appropriate immune responses. Specialized phagocytotic cells called microfold cells (M-cells) sample antigens from the intestinal lumen via transcytosis and present them to immune cells within the Peyer's patches. This process is facilitated by the feature of a thinner mucus layer found in the Peyer's patches. Lymphoid follicles containing B-cells and FDCs are located beneath the M-cells. FDCs are specialized antigen-presenting dendritic cells predominantly found in lymphoid follicles (90). T-cells are surrounding the lymphoid follicles, while other immune cells such as macrophages and dendritic cells resides within Peyer's patches throughout their lifespan. When M-cells transport antigens across the intestinal barrier to the immune cells below, innate immune cells evaluate whether the antigen is perceived as dangerous, while lymphocytes assess whether it is a recognized antigen. The antigen is drained through efferent lymphatic to nearby lymph node if no immune response I provoked.



***Figure 4.4**. Schematic overview of mucosal immune system (89). FAE: follicle-associated epithelium, SED: subepithelial dome, HEV: high endothelial venules, MLN: mesenteric lymph nodes.*

4.3 Colonization Resistance of the Gut Microbiota

The gut microbiota functions as an external metabolic organ for the host, providing absorbable nutrients, usable energy, and metabolites with specific biological roles. The gut microbiota forms a symbiotic relationship with the host, preventing and suppressing the invasion and proliferation of pathogens. This phenomenon is known as gut microbiota colonization resistance (Figure 4.5). Foreign pathogens that are able to replicate successfully, causing diseases, rely on the capacity to outcompete the original microbiota for advantageous positions (77). To begin with, the gut microbiota has the capability to produce inhibitory metabolites and bacteriocins with antibacterial properties. These substances can penetrate target cells, hinder formation of peptidoglycan, interfere with protein synthesis, and disassemble the DNA of the target cell. Short-chain fatty acids (SCFAs) generated by the symbiotic microbiota help regulate gut pH, influence the metabolic activities of invading pathogens, and suppress their proliferation.

Secondly, the indigenous gut microbiota engages in competition with pathogens for both nutritional and physical niches, thereby impeding their proliferation. For optimal growth and reproduction, bacterial strains within the same species typically need similar nutrients. Finally, the gut microbiota enhances colonization resistance by activating the immune defense mechanisms of the host. This activation involves strengthening the epithelial barrier of the gut, which in turn stimulates the host immune system to produce antimicrobial peptides and anti-inflammatory factors. The antigens on the surface of commensal microorganisms also stimulate the cells of the innate immune system to generate and release anti-inflammatory cytokines such as IL-10, IL-17, and IL-22, which are vital for preserving the integrity of the intestinal mucosal barrier (77).



Figure 4.5. *Mechanisms of the gut microbiota colonization resistance (77). Inhibitory metabolites and bacteriocins are released by the gut microbiota to kill pathogen or inhibit the proliferation. SCFAs regulates pH leading to alteration of the bacterial metabolism and suppressing the expression of virulence genes in pathogens. The immune system of the host is stimulated by the gut microbiota, producing antimicrobial peptides and anti-inflammatory factors.*

5. Cancer

Cancer is a pathological disease categorized by the development of abnormal cells that divide uncontrollably within the body, eventually leading to a mass of cells called a tumor. The tumors can be classified as either cancerous (malignant) or non-cancerous (benign), and the initial tumor that develops in the body is termed the primary tumor. Cancer cells originating from a primary tumor can spread to other parts of the body, forming secondary tumors, in a process called metastasis. According to Global Cancer Observatory, there were almost 20,000,000 cancer cases in 2020, leading to nearly 10,000,000 deaths (91), making it the second most common cause of death globally after cardiovascular diseases.

Cancers arises from the complex interplay between genetic alterations, called mutations, and environmental factors such as exposure to mutagens or carcinogens, and there exist over 100 different types of cancers which are classified according to the specific tissue or organs of invasion. Cancer cells are able to replicate infinite, unable to respond to growth-regulating signals leading to cell cycle arrest, sustained formation of new blood vessels in a process called angiogenesis, resistance to programmed cell death, and the capacity for tissue infiltration (92).

5.1 Introduction to DNA Mutagenesis and Cell Cycle Regulations

Through the cell cycle, the trillions of cells in the human body undergoes a regulated process of cell division to generate new cells. Different types of cells exhibit different lifespans. For instance, red blood cells typically survive for approximately 120 days (93), white blood cells for about 12-20 days, and intestinal epithelial cells for only 3-5 days (94). During the cell cycle, aging or damaged cell are replaced, ensuring the maintenance of normal function in the body. Disruptions in the cell cycle promotes unregulated growth and division of abnormal cells.

The emergence of a complete set of traits characterizing a cancerous cell typically necessitates more than one somatic mutation. This is a key factor contributing to the heightened incidence of cancer in older individuals. As cancer evolves through the accumulation of mutations over time, the longer one lives, the greater the likelihood of developing cancer (95). The concept of a multistep progression towards cancer is strongly substantiated by investigations into colorectal cancer, a well-understood form of human cancer affecting the colon and/or rectum.

The Genetic Code

DNA (**D**eoxyribo**n**ucleic **a**cid) is a double-stranded molecule, containing genetic information used in growth, development, functioning and reproduction of all known living organisms. DNA is a polymer, consisting of long chains of monomers called nucleotides. Each nucleotide comprises a phosphate group, a sugar molecule (deoxyribose), and one out of four nitrogenous bases: adenine (A), thymine (T), cytosine (C), or guanine (G). Adenine and guanine are *purines*, and consists of a two-ring structure, while thymine and cytosine are *pyrimidines*, consisting of only one ring (Figure 5.1). In RNA, thymine is replaced with uracil (U). The overall structure of DNA is a double helix, with the two strands run in antiparallel direction (Figure 5.1). The strands are held together by hydrogen bonds, an intermolecular force, between complementary base pairs. Adenine pairs with thymine, while cytosine pairs with guanine.



***Figure 5.1**. DNA structure. DNA forms a double helix composed of two antiparallel strands connected by complementary base pairs (96).*

Using one of the strands in DNA as a template, the genetic information stored in DNA can be transcribed into messenger RNA (mRNA) by an enzyme called RNA polymerase. The genetic information is transported from the nucleus to the cytoplasm, where ribosomes facilitate protein synthesis. During the translation process, the mRNA sequence is decoded by ribosomes in groups of three nucleotides known as codons. Each codon corresponds to a specific amino acid, which is carried to the ribosome by transfer RNA (tRNA). To ensure that the correct amino acid is added to the growing polypeptide chain, tRNA molecules carries anticodon that pair with the codons of the mRNA. Protein synthesis continues until a stop

codon is reached, signalling the termination and the release of the completed protein. There are 20 amino acids used as the building blocks of different proteins. In contrast, DNA and RNA are composed of only four different nucleotides. There are 64 different codons, where 61 codes for amino acids and 3 codes for stop signals (Figure 5.2). The genetic code is degenerate because while each codon specifies one amino acid, multiple codons can code for the same amino acid (97).

Mutations

Mutations represent fundamental alterations in the genetic code, possessing the capacity to change the RNA sequence and potentially leading to the production of non-functional proteins. These changes can emerge from various factors such as environmental influences, errors during DNA replication, or through exposure to mutagens and carcinogens. Mutagens and carcinogens are both agents that causes changes in DNA, but not all carcinogens are mutagens. By introducing mutations disruption normal cellular processes, carcinogens have the potential to initiate or promote cancer (98). The disruption of normal cellular processes can lead to uncontrolled cell division and tumorigenesis. Mutagens are substances that can damage the genetic material.

First Base in the Codon	Second Base of the Codon				Third Base in the Codon
	U	C	A	G	
U	UUU Phenylalanine UUC Phenylalanine UUA Leucine UUG Leucine	UCU Serine UCC Serine UCA Serine UCG Serine	UAU Tyrosine UAC Tyrosine UAA STOP UAG STOP	UGU Cysteine UGC Cysteine UGA STOP UGG Tryptophan	U C A G
C	CUU Leucine CUC Leucine CUA Leucine CUG Leucine	CCU Proline CCC Proline CCA Proline CCG Proline	CAU Histidine CAC Histidine CAA Glutamine CAG Glutamine	CGU Arginine CGC Arginine CGA Arginine CGG Arginine	U C A G
A	AUU Isoleucine AUC Isoleucine AUA Isoleucine AUG Methionine	ACU Threonine ACC Threonine ACA Threonine ACG Threonine	AAU Asparagine AAC Asparagine AAA Lysine AAG Lysine	AGU Serine AGC Serine AGA Arginine AGG Arginine	U C A G
G	GUU Valine GUC Valine GUA Valine GUG Valine	GCU Alanine GCC Alanine GCA Alanine GCG Alanine	GAU Aspartic Acid GAC Aspartic Acid GAA Glutamic Acid GAG Glutamic Acid	GGU Glycine GGC Glycine GGA Glycine GGG Glycine	U C A G

***Figure 5.2**. The genetic code. AUG (methionine) marks the beginning of protein synthesis during translation, while UAA, UAG and UGA are stop codons. The first nucleotide of a codon corresponds to the nucleotide at its 5' end, since the mRNA template is read by a ribosome in the 5' to 3' direction (99).*

Most mutations are *point mutations*, involving a replacement of one nucleotide with another. Point mutations can be classified into silent mutations, missense mutations, and nonsense mutations (Table 5.1). In a case where a purine is substituted for another purine (A and G), or a pyrimidine is replaced with another pyrimidine (C and T), the point mutation is classified as a transition (97). Conversely, when a purine is replaced by a pyrimidine or vice versa, the point mutation is referred to as a transversion. Since the genetic code is degenerative, most point mutations are classified as silent mutations. Silent mutations involve the substitution of a single base but do not affect the amino acid sequence of the resulting protein. For instance, the codons CCA, CCG, CCT, and CCC all encode for the same amino acid, glycine. Therefore, changing the third base of these codons does not alter the specified amino acid. As a result, silent mutations have no visible effect on the final protein product. Conversely, a missense mutation occurs when a change of a nucleotide results in the substitution of one amino acid for another in the sequence. Missense mutations can either be conservative, or non-conservative. Conservative mutations result in amino acid substitutions that preserve the overall properties and function of the protein, while non-conservative mutations lead to changes in protein structure and function due to substitutions with amino acids of significantly different properties. Nonsense mutations lead to the creation of a premature stop codon in the mRNA sequence. The premature stop codon results in a truncated, usually non-functional protein. Because of the loss of protein function, nonsense mutations are considered the most serious type of mutation and can have significant effects on cellular processes and overall organismal health (97).

Table 5.1. Classification of point mutations and the effects on the resulting protein.

Type	Description	Example	Effect
Silent	Mutated codon codes for the same amino acid	CAG (glutamine) →CA**A** (glutamine)	None
Missense	Mutated codon codes for a different amino acid	CAG (glutamine) → C**U**G (Leucine) (non-conservative)	Variable, either conservative or non-conservative
Nonsense	Mutated codon is a stop codon	CAG (glutamine) → **U**AG (stop)	Serious

Another category of mutation is known as *frameshift mutations*. A frameshift mutation occurs when the reading frame of a gene is disturbed by the deletion or insertion of one or more nucleotides (Figure 5.3). A mutation that disturbs the normal reading frame of a gene can lead to the misreading of the entire gene sequence (97). This misinterpretation may result in the incorporation of incorrect amino acids or premature terminate due to the presence of a stop codons during the protein synthesis. The DNA sequence 3'-CTC-CTC-CTC-…5', transcribes into the mRNA sequence encoding for three glutamate amino acids: 5'-GAG-GAG-GAG-…3'. If an additional cytosine (C) base is added to the sequence, the reading frame of the DNA sequence is altered: 3'-CTC-**C**CT-CCT-C…-5'. This alteration results in an additional guanine (G) base in the resultant mRNA sequence 5'-GAG-**G**GA-GGA-G…3'. The altered RNA sequence no longer encodes for one glutamate amino acid and two glycine amino acids, instead of three glutamate amino acids. Since glutamate and glycine have different properties, this missense mutation is a non-conservative mutation. This example illustrates how an insertion significantly changes the reading of mRNA codons, consequently affecting the resulting protein product in a drastic manner.



***Figure 5.3**. An insertion of a cytosine base leading to a frameshift mutation and a resulting truncated non-functional protein (100).*

The Cell Cycle

The cell cycle is the repeating pattern of cell growth, DNA synthesis and cell division. In eukaryotic cells, the cell cycle is divided into two main phases: interphase and mitosis (M). Interphase consists of G1-phase, DNA synthesis (S-phase), and G2-phase. In the G1-phase, the cell undergoes growth and prepares for DNA synthesis, where DNA is replicated. During G2-phase the cell sustains its growth and prepares for mitosis. In interphase, the cells enable to advance through the cell cycle in a systematic and regulated manner, resulting in cell division. In the mitotic (M) phase, the cell segregates during cytoplasmic division, resulting in the formation of two identical new daughter cells, which can undergo the same process.



***Figure 5.4**. Overview of the cell cycle, including the stages of interphase and mitosis (101).*

When normal somatic cells are taken out of the body, they often undergo 20-50 cell divisions before dying. In contrast, tumor cells can undergo an indefinite number of cell divisions and are said to be immortal (Figure 5.5). This characteristic facilitates the development of valuable cancer cell lines for global research purposes (102). One factor contributing to the immortality of tumor cells lies in the expression of the enzyme *telomerase*. Telomerase is an enzyme which prevents the telomeres from shortening during chromosome replication. Most normal somatic cells do not express telomerase, resulting in the loss of base pairs from their ends. Telomerase effectively regenerates new copies of repeating sequences at telomeres, enabling cancer cell telomeres to maintain a relatively consistent length across numerous cycles of cell division.



***Figure 5.5**. In cancer cells, telomerase is reactivated, enabling the continuous replenishment of telomeres (103)*

5.2 Cancer Development

Transformation of a normal cell into an abnormal cell with further progression into an invasive or malignant cell are characteristics of cancer (Figure 5.6). Cancer usually develops through three stages: initiation, promotion, and progression. The first stage of cancer development occurs through DNA damage due to genetic, metabolic, and carcinogenic factors. Radiation, chemicals, and viruses are carcinogens found to induce cancer through research with animals and humans. Carcinogenesis is the process where carcinogens cause damage of DNA molecules and involves activation of proto-oncogenes into oncogenes as well as the deactivation of tumor suppressor genes. The activation of oncogenes and deactivation of tumor suppressor genes results in uncontrolled cell proliferation and inactivation of programmed cell death. The second stage, promotion, is characterized by an extended period where defected cells from the initiation stage proliferate. The final stage of cancer development is progression, involving angiogenesis and metastasis of tumor cells that emerged during the proliferation phase. Since a single genetic mutation is insufficient for the development of cancer, cancer emerges from the cumulative effect of genetic mutations within a cell's DNA (104).



***Figure 5.6**. Carcinogenesis. Conversion of a normal cell into a cancerous cell occurs through a multistep process involving initiation, promotion, progression and metastasis (105).*

Genes are specific sequences of DNA and encodes proteins, dictating cellular activities. Proteins and RNA control various aspects of cell behavior, including the cell type, functions, and the timing of division and apoptosis. During mitosis, the process where cells divide, DNA replication occurs. Sometimes DNA replication leads to errors, called mutations. This process involves genetic alterations within individual cells or groups of cells, resulting in an abnormal cell division. If the mutations occur in non-coding regions, region that do not code for any protein, the mutation is silent and do not influence the cell. On the other hand, if a mutation happens in the coding regions of DNA, disruption of normal cellular processes can occur. Mutations may either lead to overproduction of proteins that promote cell division (oncogenes), or mutations may result in the loss of proteins that normally inhibit cell division (tumor suppressor genes). In addition to originate from natural cellular processes, mutations can be triggered by external factors known as mutagens. These include exposure to carcinogens, radiation, or ultraviolet (UV) radiation, often influenced by lifestyle choices (106). Moreover, the inheritance of defective genes from one generation to the next underscores how hereditary factors influence susceptibility to cancer. Ultimately, cancer results from cellular changes that drive uncontrolled growth and division, leading to the formation of tumors.

Cells have evolved mechanisms to efficiently repair genetic damage, because of the frequent occurrence of mutations throughout the cell cycle. These DNA repair mechanisms encompass base excision repair, nucleotide excision repair, mismatch repair, and double-strand break repair (107). Nevertheless, genetic damage can accumulate progressively, especially during rapid cell division and proliferation. Under such circumstances, there is an increased possibility of acquiring further mutations, which can compromise the cell's capacity to effectively repair DNA damage, thereby elevating the risk of genomic instability (108).

The accelerated proliferation of tumors can destroy the proper function of neighboring tissues. The tumors need supply of nutrients to grow, but the delivery of nutrients to the cancer cells is constrained by the local blood supply. However, some tumors, evade this potential limitation by secreting substances that induce the growth of blood vessels towards them. This phenomenon, characterized by the growth of blood vessels in response to secreted substances, is termed *angiogenesis* (109). The malignant nature of many cancers is underscored by their tendency to spread throughout various locations within the body, resulting in the disruption of diverse tissues and organs. While normal cells are confined to specific areas by the membrane barriers surrounding tissues or organs, tumor cells frequently acquire the capability to breach such membranes. Subsequently, these cancerous cells can traverse the bloodstream, initiating the colonization of distant tissues through a process known as *metastasis* (109). The newly formed blood vessels, facilitated by angiogenesis, provides the escape and dissemination of metastasizing cells.

5.3 Oncogenes and Tumor Suppressor Genes

Carcinogenesis is a complex, multistep process characterized by genetic alterations that impact crucial cellular pathways governing growth and development. Oncogenes are genes whose modifications result in gain-of-function effects, while alterations in tumor suppressor genes lead to loss-of-function effects, both of which contribute to the development of a malignant phenotype (110).

Cancer genes can be categorized into *proto-oncogenes* and *tumor suppressor genes.* Both tumor suppressor genes and proto-oncogenes encode proteins important for the normal function of the cell cycle (Figure 5.7). Normally tumor suppressor genes have inhibitory functions, preventing excessive cell growth and proliferation. However, when mutated, tumor suppressor genes lose the ability to inhibit uncontrolled cell growth. On the other side, proto-oncogenes are usually promoters of the cell cycle, promoting cell growth and cell division. Mutations causing in hyperactive oncogenes stimulates the cell cycle, promoting uncontrolled cell division, resulting in potentially facilitating the development of tumors (111). Mutant alleles of proto-oncogenes, known as oncogenes, has dominant effects promoting cancer development. The presence of one mutant oncogenic allele is enough to contribute to cancer-related phenotype in a diploid cell. Conversely, mutant alleles of tumor suppressor genes have act recessively to promote cancer. As a result, both copies of a tumor suppressor gene need to be mutated for the cell to show abnormal behavior in a diploid cell.



***Figure 5.7**. Mutated tumor-suppressor genes and oncogenes contribute to cancer cells (111). Normal tumor-suppressor genes regulate cell division by inhibiting excessive cell proliferation, promoting repair of damaged DNA, and triggering apoptosis in cells with irreparable damage, while normal proto-oncogenes promote cell division. Mutations in tumor-suppressor genes typically results in loss-of-function mutations, while mutations in proto-oncogenes results in gain-of-function mutations.*

Proto-oncogenes encodes proteins involved in signal transduction pathways that promote cell cycle progression under normal physiological conditions. Growth factor receptors (e.g., EGFR (112)), signal transduction proteins (e.g., Ras (113)), and transcription factors (e.g., Myc (114)) are examples of proto-oncogenes. However, mutations in proto-oncogenes can convert them into active oncogenes, in a gain-of-function mutation, by increasing gene expression or improving the efficiency of the gene product. The active oncogene significantly influences the cell cycle by promoting extensive cell proliferation, ultimately contributing to tumorigenesis.

In contrast, each normal copy of a tumor-suppressor gene encodes a protein that either decelerates cell division or protects against genome instability (115). Tumor-suppressor genes are important in restraining cell division, correcting DNA errors and promoting apoptosis. In a diploid organism, both alleles usually encode the tumor suppressor gene, ensuring that if one allele loses function, the other can still code for the proteins necessary to maintain normal cellular functions. However, when tumor-suppressor genes have lost their functions, they become promoters of cancer. Both normal alleles of the tumor-suppressor gene must be mutated or inactivated to induce an effect on the cell. Due to the loss of normal tumor-

suppressor gene, the cell may experience accelerated proliferation, increased accumulation of mutations, or a combination of both consequences.

A prominent example of a tumor suppressor gene is p53, encoded by the TP53 gene in humans (Figure 5.8). p53 is referred to as “the guardian of the genome”, because of the role in preserving genomic stability (116). In response to DNA damage, the p53 gene is transcribed and translated into proteins helping in DNA repair. If p53 undergoes mutation and loses its function, the resulting lack of protein product renders the cell incapable of repairing DNA damage. Consequently, cells with such mutations may continue to divide without undergoing cell cycle arrest. p53 mutations are implicated in approximately 50% of human cancers (117).



***Figure 5.8**. Localization of TP53 on chromosome 17, as well as several important molecular biomarkers in colorectal cancer (118).*

Cell Cycle Checkpoints

A fertilized zygote requires many rounds of cell divisions to develop into the human body. Since errors may occur during each round of cell division, precise regulation is important. Complicated mechanisms have evolved to provide cells with enough time to repair DNA damage or potential errors before segregation. Throughout the cell cycle, various checkpoints exist ensuring that mutations and DNA damage are repaired prior to division. A specific checkpoint during mitosis ensures the correct formation of the mitotic spindle. If any chromosome fails to attach to the spindle, the cell does not initiate separation of sister chromatid or anaphase chromosome movement until the correct attachment is achieved (97).

The high rates of mutations in cancer cells are often due to the disruption of DNA repair mechanisms. There are several cell cycle checkpoints, ensuring genomic stability by controlling cell division and proliferation. The first checkpoint of the cell-cycle is between G1 and S-phase, allowing DNA repair before the cell replicates its DNA. Failure to repair DNA damage before replication can result in mutations that may ultimately lead to the development of malignant cells and development of cancer.



***Figure 5.9**. Schematic overview of the cell cycle including the different cyclin-CDK complexes and cell cycle checkpoints (119).*

Cyclin-dependent kinases (CDKs), a group of protein kinases, collaborate with regulatory proteins called cyclins to regulate the progression from one phase of the cell cycle to the next. The CDK-cyclin complexes phosphorylate target proteins, leading to either activation or inactivation. The concentration of different cyclins varies throughout the cell cycle (Figure 5.10), increasing and decreasing at specific stages to modulate the activity of CDKs and synchronize cell cycle advancement. Normally, a cyclin is present at low concentrations during most of the cell cycle but undergoes an increase when its functionality is needed. However, cyclin D is present at relatively high levels throughout the cell cycle because its crucial role in regulating the transition from the G1 phase to the S phase. Unsurprisingly, the disruption of CDK regulation is a characteristic feature of cancers, making the inhibition of specific CDK members an appealing target in cancer therapy (120).



***Figure 5.10**. The concentration of cyclins throughout the cell cycle (121). The predominant active complex in the G1 phase is formed by cyclin D and CDK4/6. As the cell progresses towards the G2 phase, cyclin E binds to CDK2. Toward the end of the S phase, cyclin A-CDK2 complexes become active. Finally, during the M phase, the primary active complex is formed by cyclin B binding to CDK1.*

G1-to-S Checkpoint Role in Cancer Development

G1-to-S checkpoint is an important restriction point during the cell cycle. Cell arrest in G1-phase occurs if DNA damage is present due to factors such as radiation or chemical mutagens, ensuring that the replication of genetic material is delayed. Without the G1-to-S checkpoint, replication of damaged DNA could potentially have harmful consequences. The transition from G1-phase to S-phase is initiated by the binding of growth factors to receptors, which in turn stimulate cells to enter synthesis phase. During the transition to the S-phase, a critical step involves the phosphorylation of the retinoblastoma protein (Rb) (122).

Cyclin D is an important cyclin allowing the cell to progress to the S-phase. When there is no DNA damage, phosphorylation of Rb by cyclin D-CDK4/6 allows a transcription factor, called E2F, to activate the expression of genes essential for DNA synthesis, because the phosphorylated form of Rb protein can no longer inhibit E2F. However, in the presence of damaged DNA, unphosphorylated Rb protein functions as an inhibitor of a transcription factor called E2F. Inhibition of E2F results in no gene expression essential for DNA synthesis (Figure 5.11).



***Figure 5.11**. Overview of the G1-to-S restriction point, including the p53-pathway and the activation of p21 (123). CDK4-cyclin D and CDK2-cyclin E phosphorylates Rb, causing it to dissociate from and activate the transcription factor E2F. Transcription of genes needed for DNA replication, including that for cyclin A, is stimulated by E2F. When cells enter the synthesis (S) phase, cyclin D is destroyed, while CDK2-cyclin A is formed. DNA damage activated the p53 transcription factor, which in turn induces expression of the p21 gene. The p21 protein inhibits CDK-cyclin complexes, resulting in a G1 phase arrest. Additionally, p53 also induces the expression of many DNA repair and apoptosis genes (97).*

Mammalian cells exposed to ionizing radiation or UV light during G1-phase, also results in the activation of the p53 pathway. p53 protein is a transcription factor essential for the G1-to-S checkpoint. Initially, p53 stimulates the transcription of the CDK inhibitor known as p21. The p21 protein binds to the cyclin D-CDK4/6 complex, inhibiting the activity and preventing entry into S-phase. Additionally, p53 activates the expression of genes encoding DNA repair

enzymes. While the cell is arrested in the G1-phase by p21, these DNA repair enzymes facilitate the repair of DNA damage. The p53 pathway is deactivated once the DNA repair is accomplished, allowing the cell to progress into the S-phase (97).

The wild-type cells producing p53 undergoes apoptosis if the DNA is too damaged to be repaired. Extensive DNA damage activates the p53 transcription factor, resulting in the expression of genes involved in apoptosis. This mechanism of programmed cell death ensures the elimination of cells with significant chromosomal damage, as their reproduction could potentially contribute to the development of cancers in multicellular organisms. When Rb protein is unphosphorylated, Rb binds to E2F, preventing entry to the S-phase. Conversely, when Rb is phosphorylated, Rb releases E2F, allowing for the expression of genes necessary for S-phase entry. p21 can prevent the binding of cyclin-CDK complexes, facilitating a G1/S cell cycle arrest. This results in the activation of genes essential for progression to the S-phase of the cell cycle. Cyclin E is one of the genes activated by E2F, establishing a positive feedback mechanisms facilitating progression through the G1-phase (124).

5.4 DNA Repair Mechanisms and Their Associated Mutations in CRC

Although genetic variation has an important role in evolution, genetic stability is important for survival (56). Therefore, highly accurate mechanisms for DNA replication and efficient processes for rapidly repairing the frequent accidental mutation incidences are required to ensure genetic stability. Most of the spontaneous mutations and alterations in DNA are transient because of different DNA repair mechanisms, showing how important these mechanisms are in decreasing the occurrence of mutations. Without DNA repair mechanisms, mutations in the genetic code can contribute to the initiation and progression of cancer by transmitting the mutations. Understanding the mechanisms involved in DNA repair is essential for comprehending the molecular foundations of the development of diseases like cancer and evolving targeted therapeutic strategies.

DNA repair mechanisms encompasses a series of processes through which a cell identifies and correct errors in DNA. Each cell suffers ten thousand to one million DNA lesions per day (125), and there are two significant sources of DNA damage. In human cells, DNA damage can either originate from endogenous (internal) or exogenous (external) sources. Most endogenous DNA damage originates from the chemically active DNA undergoing hydrolytic and oxidative

reactions with water and reactive oxygen species (ROS), respectively, which are naturally occurring within cells. These inherent reactions of DNA with molecules in its environment contribute significantly to the onset of hereditary diseases and sporadic cancers (107). On the other hand, exogenous DNA damage occurs when environmental, physical, and chemical factors contribute to DNA damage. UV and ionizing radiation, alkylating agents, and crosslinking agents are examples of exogenous sources (107). The DNA repair process remains continually active as a responsive measure to structural damage in DNA.

DNA damage induces alterations in the spatial configuration of the DNA helix, a condition detectable by the cell. Once localized, specific DNA repair molecules bind to or near the damaged site, facilitating the repair process. DNA repair mechanisms are categorized into single-stranded and double-stranded repair mechanisms (Figure 5.12). There are three types of single-stranded repair mechanisms including nucleotide excision repair, base excision repair, and mismatch repair (125), while homologous recombination and nonhomologous end-joining are the two major pathways of double stranded DNA repair mechanisms (126). DNA mismatch repair (MMR) genes are pivotal in cancer initiation and progression. Defects within these genes can lead to microsatellite instability (MSI), a condition strongly associated with colorectal cancer (CRC) development (127).



***Figure 5.12**. Response to DNA damage (128). There mechanisms are mismatch repair (MMR), base-excision repair (BER), nucleotide-excision repair (NER), homologous recombination (HR), and non-homologous end-joining (NHEJ).*

Genomic instability is a pivotal feature of cancer cells and microsatellite instability (MSI) holds significant relevance in this context (129). The mismatch repair system (MMR) is important in maintaining genome stability by detecting and rectify errors occurring during DNA replication and recombination, thereby playing a crucial role in cancer prevention. MMR comprises a set of enzymes responsible for identifying DNA replication errors, such as mismatches between the two strands of DNA (Figure 5.13). There are 5 MutS homologs in humans (MSH2, MSH6, MSH3, MSH4, and MSH) and 4 MutL homologs (MLH1, PMS2, PMS1, and MLH3). Six of these genes contribute directly to the function of the mismatch repair system (130). While PMS2 has a pivotal role in the correction of single base mismatches, MLH3 may contribute to the repair of insertion-deletion loops. Additionally, when PMS2 is absent, MLH3 can also participate in the correction of mismatches (130).



***Figure 5.13**. Function of the human mismatch repair system (MMR) involving the correction of single-base mismatches (G to T, left) and insertion/deletion loops (TG insertion, right) that have appeared as replication errors in the newly synthesized DNA strand (red) (130). Abbreviations: PCNA: Proliferating cell nuclear antigen.*

6. Colorectal Cancer

Colorectal cancer (CRC) ranks as the third most common form of cancer and comes second in terms of cancer-related mortality globally (104). Since this form of cancer can develop either from the proximal colon, distal colon, or rectum, it can also be referred to as bowel cancer or rectal cancer. Statistics indicate that 41% of all the colorectal cancer cases develop in the proximal colon, while 28% of the incidences develop in the rectum, and 22% in the distal colon. Moreover, New Zealand, Europe, Australia, and North America have the highest incidences of CRC cases (Figure 6.1.). Furthermore, according to data from the Global Cancer Observatory, colorectal cancer accounted for 10.2% of diagnosed tumors and 9.2% of cancer-related deaths. By the year 2030, the rate of CRC is expected to increase by 60%, becoming a significant global health challenge (2).



Figure 6.1. *World and colorectal cancer in 2020 (131). a) Estimated age standardized incidence rate (100,000) for world countries in 2020. New Zealand, Europe, Australia, and North America have the highest incidents of colorectal cancer. b) Estimated age standardized mortality rate (100,000) for the world countries in 2020.*

There is a predicted increasing in the cases of colorectal cancer, anticipated to reach over 2 million new cases by the year of 2030 (6). Almost 90% of the incidences of colorectal cancer occur sporadically, while genetic factors or exposure to specific environmental factors contributes to the remaining cases. As mentioned in the chapter about lifestyle diseases, certain lifestyle choices such as physical inactivity, smoking, low fiber consumption, excessive intake of alcohol, and obesity impact the development of CRC. Most of the environmental factors are capable of inducing alterations in the composition of the gut microbiota. Extensive research has indicated the potential role of the gut microbiome in the progression of CRC, leading to inflammation, damage of DNA, or the production of harmful metabolites by microorganisms (6).

Chronic Inflammation and the Contribution to Colorectal Cancer

Chronic inflammation appears to be a primary factor through which dysbiosis might contribute to colonic carcinogenesis, due to the observation that many cancers originate from chronic inflammation. Patients with inflammatory bowel diseases (IBD) are known to have a higher risk of developing colorectal cancer (73). IBD is characterized by chronic inflammation within the GI-tract, resulting in a permanent immune response. IBD encompasses two primary forms: ulcerative colitis (UC) and Crohn's disease (CD) (Figure 6.2). The initial stages of IBDs involve disruptions in the normal gut microbiome, resulting in activation of the immune system. Activation of the immune system contributes to the inflammation characteristic of IBD. Considering that patients with IBD have a higher probability to develop CRC and the observed instances of dysbiosis, it is conceivable to assume that IBD-related CRC is driven by a preceding dysbiosis stage. Furthermore, colorectal cancers not directly associated with inflammatory bowel disease also seem to be influenced by inflammation. There is substantial evidence indicating that the regular use of nonsteroidal anti-inflammatory drugs (NSAIDs) reduces mortality linked to sporadic colon cancer. Moreover, NSAIDs induce adenoma regression in familial adenomatous polyposis (FAP) patients carrying a mutation in the APC-gene (132).



***Figure 6.2**. Overview of the effects of ulcerative colitis (UC) and Crohn's disease (CD) on the colon (133). Ulcerative colitis is more prevalent than Crohn's disease, primary affecting the large intestine (rectum or colon). In contrast, Crohn's disease can impact any part of the digestive tract, with the ileum being the most frequently affected site.*

Consequently, the microbiome has emerged as a leading candidate implicated in the initiation and progression of colorectal cancer. Microbial profiles of individuals with CRC and without have been used in the research. During the use of advanced sequencing techniques, such as next-generation sequencing (NGS) methods using 16s rRNA, an increase in *Fusobacterium* have been found in patients with CRC (73). Fusobacterium is a proinflammatory bacteria also prevalent in other diseases like IBD. In addition to the identification of Fusobacterium, CRC patients also have a lower abundance in bacteria that produce butyrate, including protective bifidobacteria (134). Butyrate serves as a vital energy source for colonocytes, a type of cell found in the lining of the colon and is generated through the fermentation of dietary fiber by the gut microbiota. Sustaining optimal levels of butyrate enhances gastrointestinal health in animal models by promoting the functions of colonocytes, reducing inflammation, preserving the integrity of the gut barrier, and cultivating a balance microbiome (135).

6.1 Development and Progression of Colorectal Cancer

Colorectal cancer (CRC) occurs when malignant cells develop in the large intestines, encompassing the colon and rectum. The large intestine, located in the abdominal cavity, can be divided into two spaces: the intraperitoneal space and the retroperitoneal space. The intraperitoneal space consists of the first part of the duodenum, small intestines, transverse colon, sigmoid colon, and rectum. In contrast, the retroperitoneal space contains the distal duodenum, ascending colon, descending colon, and anal canal. CRC is typically categorized based on histological subtype, site of occurrence, and the molecular pathways implicated. However, most CRCs are adenocarcinomas, constituting over 90% of CRC cases globally. Adenocarcinomas are malignant tumors that originate from the glandular epithelial cells of the colorectal mucosa (104).

CRC originates from either chromosomal instability (CIN), CpG island methylator phenotype or microsatellite instability (MSI). The CIN pathway is the most common pathway involved in the development of CRC and is responsible for 80-85% of all CRC cases (104). Loss of heterozygosity and aneuploidy are usually causing genetic instability (136). The MSI pathway is the second most common molecular pathway, associated with germline mutations in Lynch syndrome, and is observed in up to 20% of sporadic cases (137). Mutations affecting the epithelial tissues of the colon and rectum, impacting tumor suppressor genes (APC-gene and p53), oncogenes (KRAS), or genes important in the cell cycle may also affect cellular transformation (104). Likewise, modifications in epigenetic and/or genetic factors disrupting cellular pathways, such as those involved in DNA repair mechanisms, can result in microsatellite instability, causing a mutation phenotype. Additionally, non-coding RNAs, particularly microRNAs and long non-coding RNAs, have also been involved at various stages in the development of CRC (136).

While most of the colorectal cancer cases (70%) arise du to sporadic mutations (Figure 6.3) and are notably impacted by external risk factors including lifestyle choices, insufficient physical activity, and an unhealthy diet (138), only a small fraction arise due to known genetic mutations inherited within a family (139). An illustrative case is associated with the APC-gene (adenomatous polyposis coli gene), recognized as a tumor suppressor gene. Normal APC-genes produce APC-proteins important for identifying cancerous cells and forcing them to undergo apoptosis. Mutations in the APC-gene often involves the production of truncated, non-functional APC-proteins due to the introduction of a premature stop codon because of

frameshift mutation. Another notable example involves genetic mutations in DNA repair genes, crucial for repairing mutation in cellular DNA before cell division. Mutated DNA repair genes cannot repair DNA before the cells undergo cell division. Cells accumulate mutations, eventually developing into polyps and, ultimately, adenocarcinomas. Adenocarcinomas signify the malignant transformation of polyps, a result of cells dividing at an uncontrollable rate.



***Figure 6.3**. Overview of the distributions of colon cancer cases that arise in various family risk settings (140).*

Lynch Syndrome

Lynch syndrome, also known as hereditary non-polyposis colorectal cancer (HNPCC), is the most common hereditary CRC syndrome, with an estimated occurrence of 2-3% of CRC (Figure 6.3) (141). HNPCC originates from a germline pathogenic variant in a DNA mismatch repair gene (*MLH1*, *MSH2*, *MSH6*, *PMS2*), or an Epithelial Cellular Adhesion Molecule gene (EpCAM), resulting in the loss of MSH2 expression (141). Individuals with HNPCC have a germline pathogenic variant in one of the MMR genes, as well as a secondary gene inactivation through loss of heterozygosity or promoter hypermethylation. Individuals with HNPCC have a higher risk of developing CRC and other types of cancers (Figure 6.4) and causes approximately 4,300 colorectal cancers cases each year (142), because of biallelic inactivation of MMR genes inducing a hypermutated phenotype characterized by numerous errors in replicated dinucleotide repeats, termed microsatellite instability (MSI). Pathogenic variants in the

mismatch repair genes causes unregulated DNA replication, increasing the risk of carcinogenesis (141).



***Figure 6.4**. Alternative pathways to CRC in Lynch Syndrome (130). Lynch syndrome-related colorectal cancer (LS CRC) can arise from a proficient mismatch repair (pMMR) adenoma with subsequent mismatch repair (MMR) inactivation (pathway 1), or from MMR-deficient (dMMR) crypts with or without adenoma development (pathways 2 and 3). Pathway 2 involves the development of a polypoid lesion after APC inactivation and is linked with pathogenic germline variants in MSH2. Pathway 3 shows the "immediate invasive" phenotype involving CTNNB1 activation, which is characteristic of CRCs originating from MLH1 variant carriers.*

Colorectal carcinogenesis is a complex, multistep process characterized by the gradual accumulation of genetic and epigenetic alterations that culminate in disease progression and metastasis (143). Most colon tumors often grow slowly and typically does not produce symptoms until reaching a considerable size of several centimeters (3). The progression of CRC is gradual, reflecting how most types of cancers develops. Initial indications often appear as polyps, which are small, benign growths in the lining of the colon. Although the cells in these polyps have a normal appearance, the cells exhibit unusual rates of division. Consequently, the polyp can grow over time, potentially evolving into a malignant tumor capable of invading surrounding tissues. There are many types of polyps, and the various types exhibit varying propensities for malignancy. Premalignant or neoplastic polyps are polyps that are more

prone to become malignant (144). Based on the microscopic appearance, premalignant polyps can be classified into adenomatous polyps and serrated polyps (Figure 6.5). Adenomatous polyps, featuring an APC mutation, display cells resembling normal colonic mucosa cells. In contrast, serrated polyps, characterized by defects in DNA repair genes, present a sawtooth appearance (145).



***Figure 6.5**. Microscopic appearance of an adenomatous polyp and a serrated polyp (146).*

There are usually two primary genetic pathways leading to development of CRC, typically corresponding to the types of polyps associated with the origin of CRC: adenomas and SSPs (Sessile Serrated Polyps) (3). Approximately 65-70% of sporadic cancers is due to the chromosomal instability pathway (CIN-pathway), which is commonly associated with traditional adenomas. The CIN-pathway is characterized by a sequence of accumulating mutations, often originating with mutations in the *APC* gene (Figure 6.6), affecting chromosome segregation during cell division. Moreover, subsequent mutations arise in the *KRAS* oncogene, which influence cell growth, differentiation, motility, and survival. Over time, the mutations in the APC gene and the *KRAS* oncogene can lead to disruption of the function of the *p53* gene. As mentioned earlies, the *p53* gene is an important regulator of transcription and apoptosis, thereby impacting various cellular processes that ultimately lead to carcinogenesis (3). On the other side, the development of SSPs usually begins with mutations in the *BRAF* gene, resulting in both altered growths signaling and the loss of apoptosis. While mutations of the *KRAS* gene also can occur in SSPs, the occurrence is notably less frequent compared to adenomatous polyps (3).

Inherited mutations in *MLH1*, *MSH2*, *PMS2,* and the *APC* gene are associated with CRC, but are uncommon and contribute to approximately 5% of CRC cases. On the other side, by studying these inherited mutations, along with sporadically occurring APC and DNA mismatch repair mutations, has yielded crucial insights into the gradual genetic evolution from premalignant polyps to cancer (3).



Figure 6.6*. Development and stages of colorectal cancer (147). Initiation, promotion, progression, and eventually metastasis are the four stages of CRC carcinogenesis. If an adenocarcinoma becomes invasive, it has the potential to metastasize to distant organs. However, the transition from polyp formation to invasive cancer can take up to 18 years. On average, the development of metastasis occurs over a period of 9 years (147).*

Possible Predictor of Colorectal Cancer: *Fusobacterium nucleatum*

Fusobacterium nucleatum (F. nucleatum), a prevalent oral bacterium, is found in elevated levels in colorectal adenomas and adenocarcinomas (148). The presence of *F. nucleatum* in the gut has been connected to the onset of CRC. By promoting inflammation and causing activation of the immune responses within the CRC microenvironment, *F. nucleatum* facilitates tumor development. Through cell surface proteins, like FadA, Fap2, and RadD, *F. nucleatum* adheres to the intestinal epithelium, leading to generation of inflammatory factors and the recruitment of inflammatory cells creating an environment beneficial to tumor growth Figure 6.7). Moreover, through inhibiting the function of immune cells like macrophages, T-cells and NK-cells, *F. nucleatum* can induce immune suppression in the gut mucosa, thereby contributing to the progression of CRC (149). Understanding the origin and route of *F.*

nucleatum in CRC is crucial for both biological understanding and therapeutic interventions, and targeting the bacteria could potentially impede cancer progression (148).



***Figure 6.7**. F. nucleatum triggers a pro-inflammatory environment and inhibits host immunity, promoting tumor growth in the gut mucosa by binding to the colon epithelium through adhesion with FadA, Fap2, and RadD (149). The invasion of F. nucleatum enhances the infiltration of inflammatory cells, while promoting cytokine secretion, resulting in the stimulation of cellular proliferation.*

6.2 Current Diagnosis and Treatment of Colorectal Cancer

Colorectal cancer is one of the most common digestive diseases worldwide due to the inability to diagnose CRC at an early stage (150). Consequently, diagnosis at an early stage is essential for prevention. Initially, CRC are often present with no symptoms, but symptoms can develop and become noticeable as the disease progresses, depending on the location of the tumor (104). Tumors developing in the ascending (right) colon typically grow outward beyond the surface of mucosa (151). The outward growth is causing vague abdominal pain and weight loss. These tumors may ulcerate and bleed, eventually causing iron deficiency anemia. Tumors growing in the ascending colon are also allowed to grow to a considerable size before symptoms arise because the tumors do not cause bowel obstruction. Consequently, tumors arising in the right colon often results in a late diagnosis. On the other hand, tumors located on the descending (left) colon are usually infiltrating masses, forming ring-shaped masses that encircle the colonic wall, resulting in lumen narrowing known as napkin ring constriction.

Symptoms of bowel obstruction tend to occur early in these cases, causing colicky abdominal pain and blood-streaked stools (hematochezia) (151).

Diagnosis of colorectal cancer typically involves colonoscopy, stool tests (FIT and FOBT), stool DNA test, sigmoidoscopy, and CT colonography (Figure 6.8). During colonoscopy, a camera (colonoscope) is retrogradely inserted into the colon and rectum to capture images of abnormal-looking polyps and obtain a biopsy. During colonoscopy, any abnormal growths throughout the entire colon and rectum can be removed (152). Abnormal growth in the rectum and sigmoid colon can also be removed during sigmoidoscopy, using a sigmoidoscope. Clinical trials have demonstrated that undergoing sigmoidoscopy reduces the likelihood of developing and dying from CRC (152). Fecal occult blood testing (stool tests) is also commonly performed to detect evidence of gastrointestinal bleeding. Routine colonoscopy and fecal blood testing are recommended for detecting neoplastic polyps or early carcinomas, enabling early identification of CRC early and facilitating removal at an early stage. Early screening is particularly important for individuals with any family members affected by CRC, as well as those with disorders like familial adenomatous polyposis (FAP) and Lynch syndrome. FAP is an inherited disorder impacting the GI-tract, characterized by the development of hundreds or thousands of polyps within the colon or rectum (153). In individuals with FAP, it is common to observe an increase of the tumor marker CEA (carcinoembryonic antigen), a glycoprotein involved in cell adhesion. However, this finding is not highly specific (154).



***Figure 6.8**. Screening options for detection of colorectal cancer (155).*

Tumor-node-metastasis (TNM) classification is used as the staging system for CRC (137). The **T** denotes the size of the primary tumor and the depth of tumor invasion into the different layers of the colon wall. T1 denotes infiltration into the submucosa, T2 signifies an invasion of the muscularis propria, T3 indicates an invasion into the subserosa, and T4 signifies tumor penetration through all layers of the colon, extending to the visceral peritoneum or adjacent structures (156). The **N** classification indicates the extent of lymph node involvement, categorized as N0 (no involvement), N1 (involvement of 1-3 lymph nodes), and N2 (involvement of 4 or more lymph nodes) (137). Since fluid from body tissues is absorbed into lymphatic capillaries and transported to the lymph nodes for filtration, lymph nodes serve as biological filters (156). Additionally, N1c refers to nodules composed of tumor cells located in structures near the colon that does not appear as lymph nodes (157). Finally, the **M** designation signifies the existence of distant metastasis, where M0 indicates the absence of distant metastasis, while M1 denotes metastasis beyond the regional lymph nodes. M1 is further divided into M1a, M1b, and M1c, depending on the extent of cancer spread to other organs. CRC is classified into five different stages (Table 6.1) using the TNM-classification, with grading performed by pathologists after surgery. This grading provides the basis for further treatment approaches (158).

Table 6.1. Overview of colorectal staging (157).

Stage	**Stage grouping**	**Stage Description**
Stage 0	Tis, N0, M0	Stage 0 cancers are non-invasive and known as carcinoma in situ (Tis). Abnormal cells are found in the mucosa of the colon wall and have the potential to become cancerous and spread into nearby normal tissue.
Stage I	T1 or T2, N0, M0	Localized cancer. The cancer has grown through the mucosa and invaded the muscular layer of the colon/rectum.
Stage IIA	T3, N0, M0	The cancer has spread through the muscle layer of the colon wall to the serosa of the colon wall.
Stage IIB	T4a, N0, M0	Cancer has spread through the serosa of the colon wall to the tissue that lines the organs in the abdomen (visceral peritoneum).

Stage IIC	T4b, N0, M0	Cancer has spread through the serosa of the colon wall to nearby tissues.
Stage IIIA	T1 or T2, N1 or N1c, M0 OR T1, N2a, M0	The cancer has spread through mucosa of the colon wall to submucosa or to the muscle layer (muscularis propria) of the colon wall. The cancer has spread into 1-3 nearby lymph nodes or to a nodule of tumor cells in the tissues around the colon/rectum.
Stage IIIB	T3 or T4a, N1 or N1c, M0 T2 or T3, N2a, M0 T1 or T2, N2b, M0	In this stage, the cancer has penetrated through the bowel wall or to surrounding organs and into 1-3 lymph nodes or to a nodule of tumor in tissues around the colon/rectum that do not appear to be lymph nodes.
Stage IIIC	T3 or T4a, N1 or N1c, M0 T2 or T3, N2a, M0 T1 or T2, N2b, M0	Regardless of how deep the cancer has grown, it has spread into 4 or more lymph nodes, but still not spread to other distant parts of the body.
Stage IVA	Any T, any N, M1a	Cancer has spread to one distant area or organ, such as the liver, lung, ovary, or a distant lymph node.
Stage IVB	Any T, any N, M1b	The cancer has spread to more than one area or organ distant to the colon, such as the liver, lung, ovary, or a distant lymph node.
Stage IVC	Any T, any N, M1c	The cancer has spread to the peritoneum and may have spread to other areas or organs.



***Figure 6.9**. A visual representation of the different stages, 0-IV, of CRC development (159).*

Treatments of Colorectal Cancer

The primary treatment for early stage CRC is surgical removal, while systematic therapy like chemotherapy, radiation, and immunotherapy are standard treatments for metastatic CRC (mCRC) (160). Treatment for patients with CRC is largely bases on the stage of development of the cancer, but other factors may also be important (161). There are seven types of standard treatments for patients suffering from colorectal cancer: surgery, radiofrequency ablation, cryosurgery, chemotherapy, radiation therapy, targeted therapy and immunotherapy (158). Generally, early stages confined to the colon wall are often treated with surgery. Nevertheless, individuals with stage II and III often receive chemotherapy after surgery, enhancing the probability of eliminating the disease. In addition, radiation therapy with chemotherapy may be used either before or after surgery for individuals with stage II or III rectal cancer. Unfortunately, metastatic cancers in stage IV are typically incurable, but chemotherapy or surgery may be used to ease symptoms.

Systemic therapy is the primary treatment strategy for mCRC, with the purpose to treat cancer cells throughout the body. Systematic therapy includes chemotherapy, targeted therapy, and immunotherapy. Chemotherapy is usually the initial approach for treating mCRC, employing medications designed to eradicate cancer cells. Chemotherapy drugs are intended to stop or slow tumor growth by effectively destroying cancerous cells (162). In addition to the use of chemotherapy, targeted therapy may be used for patients with specific genetic mutations, like KRAS or BRAF mutations. Furthermore, immunotherapy medications may be explored for patients with tumors with particular genetic biomarkers, such as microsatellite instability-high (MSI-H) or mismatch repair deficiency (dMMR) (163).

Targeted Therapy for Colorectal Cancer

With targeted therapy, medications are used to target specific genes, proteins, or tissue environment of cancer cells. By using these drugs, the growth and spread of cancer cells are blocked, resulting in limiting the damage to normal, healthy cells. Targeted therapy uses drugs that enter the bloodstream, thereby reaching almost every area of the body and making them useful against metastatic cancers (164). There are several types of medications used in targeted therapy for the treatment of colorectal cancer (Figure 6.10). Vascular endothelial growth factor (VEGF) is a protein crucial for facilitating angiogenesis, the process where tumors develop new blood vessels to acquire necessary nutrients for growth. Bevacizumab is

a medication which specifically target and inhibit the activity of VEGF, and can be used in the treatment of certain colon or rectal cancers (164).

Moreover, monoclonal antibodies (mAbs) like Cetuximab and Panitumumab blocks epidermal growth factor receptor (EGFR), which is a protein that helps cancer grow. The MAPK/ERK pathway, also known as the Ras/RAF/MEK/ERK pathway (Figure 6.10), stands as the most well-known pathway in CRC pathogenesis, with mutations in genes of this pathway reported in approximately 50% of CRC patients (165). The MAPK/ERK pathway is initiated by the binding of EGF (epidermal growth factor) to EGFR (epidermal growth factor receptor) (166). The EGFR signaling pathway has important roles in various cellular functions such as the growth, proliferation, and survival of normal, healthy cells. Since the suggestion that the Ras/RAF/MEK/ERK pathway governs cell growth, proliferation, and survival, any dysregulation in its function leads to increased cell proliferation, prolonged survival, angiogenesis, anti-apoptosis, invasion, and metastasis. Consequently, such dysregulation can initiate malignant transformation and tumor progression (167).

Additionally, the EGFR/MAPK signaling pathway has been implicated in oncogenic processes, thus playing a crucial role in tumor growth and the progression of CRC (167). Therefore, drugs targeting EGFR (EGFR inhibitors) and the signaling molecules can be useful to treat some of the advanced colon or rectal cancers (164). However, if tumors have a specific mutation in the *KRAS*, *NRAS* or *BRAF* gene, these medications do not work as well. Mutation in the *BRAF* gene results in the production of an abnormal BRAF protein. Certain drugs such as Encorafenib, a BRAF inhibitor, is designed to specifically target the abnormal BRAF protein. This therapeutic approach can be employed in the treatment of colorectal cancer among patients exhibiting mutations in the *BRAF* gene. Encorafenib has shown effectiveness in reducing or slowing the progression of colorectal cancer in certain individuals with metastatic cancer when combined with Cetuximab or Panitumumab. Additionally, the combination therapy has demonstrated the potential to extend the survival of individuals with advanced colorectal cancer (164).



***Figure 6.10**. Overview of target therapy and drug interventions used in colorectal cancer treatment (168). Abbreviations: **HGF**: Hepatocyte Growth Factor; **c-MET**: Mesenchymal-Epithelial Transition Factor; **EGFR**: Epidermal Growth Factor Receptor; **VEGF**: Vascular Endothelial Growth Factor; **VEGFR**: Vascular Endothelial Growth Factor Receptor; **HER2**: Human Epidermal Growth Factor 2; **PD-1**: Programmed Death-1; **PD-L1**: Programmed Death Ligand 1; **B7**: B7 ligand; **CTLA-4**: Cytotoxic T-lymphocyte-associated Antigen 4; **PI3K**: Phosphoinositide 3-kinase; **AKT**: Protein Kinase B, also known as PKB; **mTOR**: Mammalian Target of Rapamycin; **RAS**: Rat Sarcoma; **RAF**: Rapidly Accelerated Fibrosarcoma; **MEK**: Mitogen-Activated Protein Kinase; **ERK**: Extracellular Signal Regulated Kinase; **5-FU**: 5-fluorouracil; **OXA**: Oxaliplatin.*

Despite advancements in comprehensive cancer therapy, metastatic CRC still presents a challenging prognosis. Human epidermal growth factor receptor 2 (HER2) serves as a well-established oncogenic driver and has been effectively targeted in breast and gastric cancers (169). In a small percentage (approximately 5%) of individuals diagnosed with CRC, there exists an elevated expression of HER2 (Figure 6.11) on the surface of cancerous cells. HER2 is a protein known to stimulate cellular growth. Consequently, HER2 is an emerging biomarker in CRC and most of the HER2 alterations in CRC encompasses gene amplification and missense mutations, found in 7-8% of CRC cases (170). Drugs targeting the HER2 protein can be beneficial in treating these types of cancers (164). In 2023, the FDA granted accelerated approval for the use of Tucatinib in combination with Trastuzumab (Herceptin) to treat patients with unresectable or metastatic RAS wild-type, HER2 positive colorectal cancer who have previously received fluoropyrimidine, oxaliplatin, and irinotecan therapies (171).



***Figure 6.11**. HER2 contributes to regular cell proliferation (172). In some cancers, tumor cells produce excess copies of the gene responsible for the HER2 protein through gene amplification. Monoclonal antibodies binds to the HER2-receptors, preventing the tumor cells to receive signals that stimulate cell growth (172).*

Immunotherapy for Colorectal Cancer

The ability of cancer cells to evade immune surveillance presents a significant challenge. Therefore, the goal of immunotherapy is to recruit immune cells and eliminate tumor cells by preventing the evasion of immune detection (143). Immunotherapy is a type of biological therapy using substances made from living organisms to treat cancer (173), and has emerged as a fundamental aspect of treatment in individuals diagnosed with either early or advanced-stage colorectal cancer, particularly when the tumor exhibits dMMR or MSI-H characteristics (174). The medication used in immunotherapy improves the immune system of the patients to better recognize and destroy cancer cells. Several types of cancer immunotherapy exist, including immune checkpoint inhibitors (ICIs), chimeric antigen receptor (CAR) T-cell therapy, oncolytic virus therapy, and cancer vaccines. A class of drugs called immune checkpoint inhibitors are commonly used in the treatment of patients with CRC (175). Monoclonal antibodies (mAbs) represents a type of biological medication synthesized in laboratories with the purpose of targeting and binding to specific molecules present on the surface of immune system cells (175). The immune system is equipped with checkpoints serving as regulatory switches, controlling the intensity of the immune responses. These checkpoints enable the adjustment of immune responses to abnormal cells, such as cancer cells, bacteria, and virus-infected cells, while preventing excessive damage to healthy cells (175).

Several checkpoint receptors like CTLA-4 (Cytotoxic T-Lymphocyte-associated Antigen 4) and PD-1 (Programmed Cell Death Protein 1) are present on the surface of T-cells. Tumor cells can produce proteins that are able to bind to these receptors, effectively deactivating the immune checkpoints (Figure 6.12). Consequently, inhibitors targeting the PD-1/PD-L1 pathway, as well as CTLA-4 are used as medication in immunotherapy. Currently, FDA-approved immune checkpoint inhibitors include Ipilimumab, Pembrolizumab, Nivolumab, Atezolizumab and Durvalumab. Pembrolizumab and Nivolumab, as well as the combination of Nivolumab and Ipilimumab, are approved for CRC treatment in the USA (176).

Although ICIs have shown notable effectiveness across a range of malignancies, only some of the patients experience favorable responses (177). Of the PD-1 inhibitors, drugs like Pembrolizumab and Nivolumab are used to target PD-1 on the surface of T-cells, while Atezolizumab and Durvalumab inhibit PD-L1 on tumor cells. The activation of PD-1/PD-L1 pathway in normal immune system can inhibit the immune function of T-cells while promoting the inhibitory effects of Tregs. Conversely, tumor cells evade the anti-tumor activity of T-cells by expressing PD-L1 on the cell surface, evading recognition by the immune system (143). Antibodies targeting the PD-1/PD-L1 pathway leads to disruption in the interaction between PD-1 and PD-L1, thereby enabling T-cells to trigger an immune response against tumor cells (178).

Another medication that enhances the immune responses is Ipilimumab (174). Ipilimumab is targeting CTLA-4, a molecular ligand belonging to the inhibitory molecule of the immunoglobulin superfamily and expressed on some activated T-cells (143). CTLA-4 plays a crucial role in regulating the immune responses and maintaining immunological balance (179). Since the structure of CTLA-4 is homologous to CD28, CTLA-4 can bind to B7 ligand (CD80/CD86). Furthermore, CTLA-4 exhibit a higher affinity for the B7 molecule compared to CD28. The interaction between CTLA-4 and B7 leads to suppression of T-cell proliferation, activation, and production of cytokines, thereby restraining T-cells from destroying cancer cells (143). On the contrary, blockade of CTLA-4 using anti-CTLA-4 antibodies has demonstrated to inhibit tumor progression by enhancing the activity of effector T-cell while suppressing regulatory T-cells. Ipilimumab inhibits CTLA-4, thereby preventing it from binding to B7 on a tumor cell. This action releases the “brakes” on the immune system, enhancing the capability of T-cells to eliminate cancer cells more effectively (180).



Figure 6.12. *Overview of the anticancer mechanisms of PD-1/PD-L1 and CTLA-4 inhibitors (181). Endogenous peptides are presented on MHC class I molecules on the surface of human cells, including cancer cells. Monoclonal antibodies (mAbs) that either target the inhibitory receptors on T-cells or the corresponding ligands on cancer cells counteract inhibitory signaling. This action facilitates the activation of T-cells and promotes the elimination of tumor cells through cytotoxic mechanisms.*

6.3 Future Treatments in CRC

Recent advancements in colorectal cancer (CRC) treatment including immune checkpoint inhibitors (ICIs), chimeric antigen receptor (CAR) T-cell therapy, T-cell receptor (TCR) modifications, and cytokine therapy, have demonstrated effectiveness (160). Additionally, recent research exploring the potential of probiotics, RNA-based therapies (such as small interfering RNA (siRNA), microRNA (miRNA), and RNA aptamers), oncolytic viral therapies, and natural products in CRC treatment, has also showed promising results. Despite these developments, the survival rate for patients in advanced stages remains a significant challenge in the world. Studying the pathophysiology of CRC is important to improve treatment approaches, as well as enhancing existing therapies like radiation therapy, targeted therapy, endoscopic resection, chemotherapy, and immunotherapy (160).

Chimeric Antigen Receptor T-cell Therapy

Chimeric antigen receptor (CAR) T-cell therapy is an innovative form of immunotherapy used to treat certain types of cancer (Figure 6.13). The CAR T-cell approach represents a personalized immunotherapy strategy centered on genetically engineered allogeneic (T-cells from a healthy blood donor) or autologous (T-cells harvested from the blood of the patient) synthetic T-cells expressing chimeric antigen receptors (182). CAR T-cell therapy technology extracts T-cells from the patients, which are modified in a laboratory. The genetic information is introduced into a modified and inactive virus, reprogramming the T-cells. In the laboratory special receptors called chimeric antigen receptors (CARs) are produced on the cell surface of the T-cells, designed to recognize and bind to antigens found on the surface of cancer cells, thereby destroying them (183). Even though CAR T-cell therapy has huge potential and is anticipated to offer significant benefits in the future, several limitations must be resolved before CARs achieve universally acceptance, particularly in solid cancers (184).



***Figure 6.13**. Schematic overview of the technology of Chimeric antigen receptor (CAR) T-cell therapy (185). The production of CAR T-cells involves extraction of normal T-cells from the peripheral blood from the patient (autologous) or a donor (allogeneic). Subsequently, the extracted T-cells are enriched and subjected to CAR vector delivery, using either viral or non-viral vector systems, into the T-cells in vitro. Finally, the CAR T-cells undergo expansion before being reintroduced into the bloodstream of the patient. CEA, MUC-1 and EpCAM are some of the CAR T-cell targets in CRC.*

The primary challenge in the progression of CAR T-cell therapies lies in the identification of target antigens specific to each type of cancer (185). Cancer-associated antigens are categorized as tumor-associated antigens (TAAs) and tumor-specific antigens (TSAs), also known as neoantigens. TAAs are antigens overexpressed in tumor cells, but also present on normal cells (186). Clinical trials investigating CAR T-cell therapy for CRC are exploring a range of antigen targets (184), including CEA (Carcinoembryonic antigen), CD133, C-Met, EGFR, NKG2DL (Natural Killer Group 2 member D Ligand), EpCAM (Epithelial Cell Adhesion Molecule), MUC-1, MLSN (mesothelin), PSMA (Prostate-Specific Membrane Antigen), GUCY2C (Guanylate Cyclase-C), and HER2 (Figure 6.13) (184).

CEA, along with EpCAM, represents one of the extensively investigated targets for anti-CRC CAR T-cells. Additionally, second-generation CAR T-cells directed against CEA have exhibited remarkable anti-tumor efficacy both *in vitro* and *in vivo*, with enhanced outcomes observed when combined with interleukins such as IL-12 (185). Figure 6.14 shows some of the new CAR T-cell strategies targeting specific antigens like CD166/CD318, PDL-1, GUCY2Y, and GB3. CD166/CD318 are CD6 receptors highly expressed in CRC, showing potent cytotoxicity targeting CRCs stem cells and can therefore be a promising approach for the therapy of CRC (131). GUCY2C, a membrane-bound receptor expressed in both human primary and metastatic CRC, generates the second messenger cGMP, when activated by hormone ligands like guanylin or uroguanylin. cGMP regulates intestinal homeostasis, cancer, and obesity (187). GUCY2C is highly expressed in 95% of metastatic CRC, making it a significant tumor marker (132). GB3 (Globotriaosylceramide) is a receptor expressed on the surface of many neoplasms of the digestive tract, making it a target for use in future CAR T-cell therapy (133).



***Figure 6.14**. Overview of new CAR-T cell strategies targeting specific antigens like PDL-1, CD166/CD318, GB3, and GUCY2C, which may become new immunotherapeutic approaches for inducing apoptosis in CRC (187). Abbreviations: GB3: globotriaosylceramide; GUCY2Y: Guanylate Cyclase-C.*

The primary advantage of CAR T-cell therapy compared to other types of adaptive T-cell therapy is its ability to interact with target antigens expressed on the cell surface independently of the major histocompatibility complex (MHC) receptor (184). Moreover, CARs ensure high affinity even at low antigen density, enhancing the effectiveness of targeting and destroying cancer cells (182). There are three CAR T-cell therapies (axicabtagene ciloleucel, tisagenlecleucel, and brexucabtagene autoleucel) approved by both the FDA and the European Medicines Agency (EMA) for commercial use. These therapies are indicated for the treatment of leukemia and lymphomas, specifically targeting CD19-positive hematological malignancies (185). However, the effectiveness of CAR T-cell therapy used as treatment of solid tumors like CRC is yet to be established (176). There are multiple biological obstacles making it difficult for the successful migration of T-cells from the bloodstream to the stromal components of solid tumors. The different outcomes of CAR T-cell therapy between hematological malignancies and solid tumors may be attributed to these barriers (183).

7. Concluding Remarks and Future Perspectives

This thesis provides a comprehensive overview of the intricate interplay between how alterations in the gut microbiome composition and its metabolites contributes to dysbiosis, inflammation and ultimately the initiation of colorectal cancer. Additionally, it provides insights into the different mechanisms of the immune system involved in identifying and eliminating cancer cells among other threats, offering valuable understandings into tumor immunology and host defense mechanisms.

Colorectal cancer remains a significant public health concern all over the world. However, early diagnosis and detection can significantly reduce CRC-related mortality and improve patient outcome. Current treatments, including surgery, chemotherapy, and targeted therapy, have shown favorable result as treatment of CRC, while emerging therapies such as immunotherapy hold promise for future treatment of CRC. Nevertheless, most of the incidence and mortality of CRC are modifiable through the adoption of a healthy lifestyle. By focusing on improving gut health through dietary interventions, probiotic supplementation, and lifestyle modifications, individuals can reduce the incidences of dysbiosis, inflammation, metabolic disturbances, and DNA damage—factors known to contribute to CRC development.

Consequently, enhancing our understanding of the relationship between the gut microbiota and its influence on our overall health, is essential for developing more effective prevention and treatment approaches. Additionally, optimizing gut health supports immune regulation and surveillance, thereby enhancing the capacity of the human body to detect and eliminate malignant transformations. Moving forward, continued research and public health initiatives aimed at improving gut health are crucial for advancing CRC prevention strategies and reducing the burden of this disease and improving patient survival and quality of life.

8. References

1. American Cancer Society [Internett]. What Is Colorectal Cancer? Tilgjengelig på: https://www.cancer.org/cancer/types/colon-rectal-cancer/about/what-is-colorectal-cancer.html
2. Siddiqui R, Boghossian A, Alharbi AM, Alfahemi H, Khan NA. The Pivotal Role of the Gut Microbiome in Colorectal Cancer. Biology. 9. november 2022;11(11):1642.
3. Simon K. Colorectal cancer development and advances in screening. Clin Interv Aging. 2016;11:967–76.
4. Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin. mai 2023;73(3):233–54.
5. What is colorectal cancer? [Internett]. Tilgjengelig på: https://www.kreftregisteret.no/en/screening/colorectalscreen-norway/what-is-colorectal-cancer/
6. Kim J, Lee HK. Potential Role of the Gut Microbiome In Colorectal Cancer Progression. Front Immunol. 2021;12:807648.
7. Li J, Zhang AH, Wu FF, Wang XJ. Alterations in the Gut Microbiota and Their Metabolites in Colorectal Cancer: Recent Progress and Future Prospects. Front Oncol. 2022;12:841552.
8. Akbar N, Khan NA, Muhammad JS, Siddiqui R. The role of gut microbiome in cancer genesis and cancer prevention. Health Sci Rev. mars 2022;2:100010.
9. EARLY DETECTION MATTERS: THE CRUCIAL ROLE OF COLORECTAL CANCER [Internett]. Tilgjengelig på: https://gatgi.com/blog/early-detection-matters-the-crucial-role-of-colorectal-cancer-screening/
10. Roy AL, Conroy RS. Toward mapping the human body at a cellular resolution. Mol Biol Cell. 1. august 2018;29(15):1779–85.
11. Biochemistry, Nutrients. I: StatPearls [Internet] [Internett]. Tilgjengelig på: https://www.ncbi.nlm.nih.gov/books/NBK554545/
12. Physiology, Gastrointestinal. I: StatPearls [Internet] [Internett]. Tilgjengelig på: https://www.ncbi.nlm.nih.gov/books/NBK537103/
13. Cleveland Clinic [Internett]. Digestive System. Tilgjengelig på: https://my.clevelandclinic.org/health/body/7041-digestive-system
14. Cleveland Clinic [Internett]. Peristalsis. Tilgjengelig på: https://my.clevelandclinic.org/health/body/22892-peristalsis
15. CONCEPTS OF BIOLOGY – 1ST CANADIAN EDITION [Internett]. 15.3 Digestive System Processes. Tilgjengelig på: https://opentextbc.ca/biology/chapter/15-3-digestive-system-processes/
16. What major organs are components of the digestive tract? What are the accessory organs of the digestive system? [Internett]. Tilgjengelig på: https://socratic.org/questions/what-major-organs-are-components-of-the-digestive-tract-what-are-the-accessory-o
17. Rao JN, Wang JY., San Rafael (CA): Morgan & Claypool Life Sciences. Regulation of Gastrointestinal Mucosal Growth [Internett]. Tilgjengelig på: https://www.ncbi.nlm.nih.gov/books/NBK54098/
18. Tori de Lacy. Layers of the Gastrointestinal Tract [Internett]. 2023. Tilgjengelig på: https://geekymedics.com/layers-of-the-gastrointestinal-tract/
19. What are the names of the tissue layers of the stomach? [Internett]. Tilgjengelig på: https://socratic.org/questions/what-are-the-names-of-the-tissue-layers-of-the-stomach
20. Physiology, Digestion. I: StatPearls [Internet] [Internett]. Tilgjengelig på: https://www.ncbi.nlm.nih.gov/books/NBK544242/
21. Peyrot des Gachons C, Breslin PAS. Salivary Amylase: Digestion and Metabolic Syndrome. Curr Diab Rep. oktober 2016;16(10):102.
22. Campbell NA, Urry LA, Cain ML, Wasserman SA, Minorsky PV, Reece JB. Biology: a global approach. Eleventh edition, global edition. New York, NY: Pearson; 2018. 1342 s.
23. The Stomach and The Pancreas [Internett]. Tilgjengelig på: https://courses.lumenlearning.com/nemcc-ap2/chapter/the-stomach/
24. Engevik AC, Kaji I, Goldenring JR. The Physiology of the Gastric Parietal Cell. Physiol Rev. 1. april 2020;100(2):573–602.
25. Rajiv Heda; Fadi Toro; Claudio R. Tombazzi. Physiology, Pepsin. I: StatPearls [Internet] [Internett]. Tilgjengelig på: https://www.ncbi.nlm.nih.gov/books/NBK537005/
26. Jason T. Collins; Amanda Nguyen; Madhu Badireddy. Anatomy, Abdomen and Pelvis, Small Intestine. I: StatPearls [Internet] [Internett]. Tilgjengelig på: https://www.ncbi.nlm.nih.gov/books/NBK459366/

27. The Editors of Encyclopaedia Britannica. Small intestine- anatomy [Internett]. Tilgjengelig på: https://www.britannica.com/science/small-intestine
28. The Editors of Encyclopaedia Britannica. Large intestine [Internett]. Tilgjengelig på: https://www.britannica.com/science/large-intestine
29. Ogunrinola GA, Oyewale JO, Oshamika OO, Olasehinde GI. The Human Microbiome and Its Impacts on Health. Int J Microbiol. 12. juni 2020;2020:1–7.
30. Hou K, Wu ZX, Chen XY, Wang JQ, Zhang D, Xiao C, mfl. Microbiota in health and diseases. Signal Transduct Target Ther. 23. april 2022;7(1):135.
31. Conlon MA, Bird AR. The impact of diet and lifestyle on gut microbiota and human health. Nutrients. 24. desember 2014;7(1):17–44.
32. Aggarwal N, Kitano S, Puah GRY, Kittelmann S, Hwang IY, Chang MW. Microbiome and Human Health: Current Understanding, Engineering, and Enabling Technologies. Chem Rev. 11. januar 2023;123(1):31–72.
33. Bull MJ, Plummer NT. Part 1: The Human Gut Microbiome in Health and Disease. Integr Med Encinitas Calif. desember 2014;13(6):17–22.
34. Quaglio AEV, Grillo TG, De Oliveira ECS, Di Stasi LC, Sassaki LY. Gut microbiota, inflammatory bowel disease and colorectal cancer. World J Gastroenterol. 14. august 2022;28(30):4053–60.
35. Farhud DD. Impact of Lifestyle on Health. Iran J Public Health. november 2015;44(11):1442–4.
36. Afzaal M, Saeed F, Shah YA, Hussain M, Rabail R, Socol CT, mfl. Human gut microbiota in health and disease: Unveiling the relationship. Front Microbiol. 26. september 2022;13:999001.
37. Wiertsema SP, van Bergenhenegouwen J, Garssen J, Knippels LMJ. The Interplay between the Gut Microbiome and the Immune System in the Context of Infectious Diseases throughout Life and the Role of Nutrition in Optimizing Treatment Strategies. Nutrients. 9. mars 2021;13(3):886.
38. Appleton J. The Gut-Brain Axis: Influence of Microbiota on Mood and Mental Health. Integr Med Encinitas Calif. august 2018;17(4):28–32.
39. Oroian BA, Ciobica A, Timofte D, Stefanescu C, Serban IL. New Metabolic, Digestive, and Oxidative Stress-Related Manifestations Associated with Posttraumatic Stress Disorder. Santibanez JF, redaktør. Oxid Med Cell Longev. 20. desember 2021;2021:1–18.
40. Sato Y, Tsujinaka S, Miura T, Kitamura Y, Suzuki H, Shibata C. Inflammatory Bowel Disease and Colorectal Cancer: Epidemiology, Etiology, Surveillance, and Management. Cancers. 17. august 2023;15(16):4154.
41. Sawicki T, Ruszkowska M, Danielewicz A, Niedźwiedzka E, Arłukowicz T, Przybyłowicz KE. A Review of Colorectal Cancer in Terms of Epidemiology, Risk Factors, Development, Symptoms and Diagnosis. Cancers. 22. april 2021;13(9):2025.
42. Rychter AM, Łykowska-Szuber L, Zawada A, Szymczak-Tomczak A, Ratajczak AE, Skoracka K, mfl. Why Does Obesity as an Inflammatory Condition Predispose to Colorectal Cancer? J Clin Med. 23. mars 2023;12(7):2451.
43. O'Keefe SJD, Li JV, Lahti L, Ou J, Carbonero F, Mohammed K, mfl. Fat, fibre and cancer risk in African Americans and rural Africans. Nat Commun. 28. april 2015;6(1):6342.
44. Aykan NF. Red Meat and Colorectal Cancer. Oncol Rev. 10. februar 2015;9(1):288.
45. Shin Y, Han S, Kwon J, Ju S, Choi T, Kang I, mfl. Roles of Short-Chain Fatty Acids in Inflammatory Bowel Disease. Nutrients. 21. oktober 2023;15(20):4466.
46. Ren Y, Wu J, Wang Y, Zhang L, Ren J, Zhang Z, mfl. Lifestyle patterns influence the composition of the gut microbiome in a healthy Chinese population. Sci Rep. 2. september 2023;13(1):14425.
47. Tang D, Kang R, Coyne CB, Zeh HJ, Lotze MT. PAMP s and DAMP s: signal 0s that spur autophagy and immunity. Immunol Rev. september 2012;249(1):158–75.
48. Shevyrev D, Tereshchenko V, Berezina TN, Rybtsov S. Hematopoietic Stem Cells and the Immune System in Development and Aging. Int J Mol Sci. 20. mars 2023;24(6):5862.
49. Raza Y, Salman H, Luberto C. Sphingolipids in Hematopoiesis: Exploring Their Role in Lineage Commitment. Cells. 22. september 2021;10(10):2507.
50. Marshall JS, Warrington R, Watson W, Kim HL. An introduction to immunology and immunopathology. Allergy Asthma Clin Immunol Off J Can Soc Allergy Clin Immunol. 2018;14(Suppl 2):49.
51. Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 1. oktober 2018;32(19–20):1267–84.
52. James Perkins. Innate vs. adaptive immunity [Internett]. 2011. Tilgjengelig på: https://www.rit.edu/spotlights/innate-vs-adaptive-immunity

53. The components of the immune system. I: Immunobiology: The Immune System in Health and Disease 5th edition [Internett]. Tilgjengelig på: https://www.ncbi.nlm.nih.gov/books/NBK27092/
54. Li Y, Jin L, Chen T. The Effects of Secretory IgA in the Mucosal Immune System. BioMed Res Int. 2020;2020:2032057.
55. Antigen receptor structure and signaling pathways. I: Immunobiology: The Immune System in Health and Disease 5th edition [Internett]. Tilgjengelig på: https://www.ncbi.nlm.nih.gov/books/NBK27130/
56. Alberts B, Johnson A, Lewis J, et al. Molecular Biology of the Cell. 4th edition. [Internett]. Tilgjengelig på: https://www.ncbi.nlm.nih.gov/books/NBK26879/
57. Antigen receptors on lymphocytes [Internett]. Tilgjengelig på: https://bio1152.nicerweb.com/Locked/media/ch43/antigen_receptors.html
58. B Cell Overview [Internett]. Tilgjengelig på: https://www.thermofisher.com/us/en/home/life-science/cell-analysis/cell-analysis-learning-center/immunology-at-work/b-cell-overview.html
59. Cleveland Clinic [Internett]. T-Cells. Tilgjengelig på: https://my.clevelandclinic.org/health/body/24630-t-cells
60. Workman CJ, Szymczak-Workman AL, Collison LW, Pillai MR, Vignali DAA. The development and function of regulatory T cells. Cell Mol Life Sci. august 2009;66(16):2603–22.
61. Vojdani A, Koksoy S, Vojdani E, Engelman M, Benzvi C, Lerner A. Natural Killer Cells and Cytotoxic T Cells: Complementary Partners against Microorganisms and Cancer. Microorganisms. 22. januar 2024;12(1):230.
62. Somak Banerjee. MHC Molecules- Definition, Properties, Class, Types, Pathways [Internett]. 2022. Tilgjengelig på: https://microbenotes.com/mhc-molecules/
63. Alberts B, Johnson A, Lewis J, et al. Helper T Cells and Lymphocyte Activation [Internett]. Tilgjengelig på: https://www.ncbi.nlm.nih.gov/books/NBK26827/
64. Alegre ML, Frauwirth KA, Thompson CB. T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol. desember 2001;1(3):220–8.
65. Jens Vikse. IMMU. Lærebok i immunologi.
66. Meng X, Layhadi JA, Keane ST, Cartwright NJK, Durham SR, Shamji MH. Immunological mechanisms of tolerance: central, peripheral and the role of T and B cells. Asia Pac Allergy [Internett]. 8. desember 2023 [sitert 3. mai 2024]; Tilgjengelig på: https://journals.lww.com/10.5415/apallergy.0000000000000128
67. Waldmann TA. Cytokines in Cancer Immunotherapy. Cold Spring Harb Perspect Biol. 3. desember 2018;10(12):a028472.
68. Kany S, Vollrath JT, Relja B. Cytokines in Inflammatory Disease. Int J Mol Sci. 28. november 2019;20(23):6008.
69. Baranovski BM, Freixo-Lima GS, Lewis EC, Rider P. T Helper Subsets, Peripheral Plasticity, and the Acute Phase Protein, α1-Antitrypsin. BioMed Res Int. 2015;2015:184574.
70. Magombedze G, Reddy PBJ, Eda S, Ganusov VV. Cellular and population plasticity of helper CD4+ T cell responses. Front Physiol [Internett]. 2013 [sitert 19. april 2024];4. Tilgjengelig på: http://journal.frontiersin.org/article/10.3389/fphys.2013.00206/abstract
71. Isvoranu G, Chiritoiu-Butnaru M. Therapeutic potential of interleukin-21 in cancer. Front Immunol. 2024;15:1369743.
72. Voronova V, Vislobokova A, Mutig K, Samsonov M, Peskov K, Sekacheva M, mfl. Combination of immune checkpoint inhibitors with radiation therapy in cancer: A hammer breaking the wall of resistance. Front Oncol. 5. desember 2022;12:1035884.
73. Mármol I, Sánchez-de-Diego C, Pradilla Dieste A, Cerrada E, Rodriguez Yoldi MJ. Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer. Int J Mol Sci. 19. januar 2017;18(1):197.
74. Miko E, Csaszar A, Bodis J, Kovacs K. The Maternal-Fetal Gut Microbiota Axis: Physiological Changes, Dietary Influence, and Modulation Possibilities. Life Basel Switz. 15. mars 2022;12(3):424.
75. Navale AM, Paranjape AN. Glucose transporters: physiological and pathological roles. Biophys Rev. mars 2016;8(1):5–9.
76. Andrioaie IM, Duhaniuc A, Nastase EV, Iancu LS, Luncă C, Trofin F, mfl. The Role of the Gut Microbiome in Psychiatric Disorders. Microorganisms. 9. desember 2022;10(12):2436.
77. Zhao M, Chu J, Feng S, Guo C, Xue B, He K, mfl. Immunological mechanisms of inflammatory diseases caused by gut microbiota dysbiosis: A review. Biomed Pharmacother. august 2023;164:114985.

78. Baldelli V, Scaldaferri F, Putignani L, Del Chierico F. The Role of Enterobacteriaceae in Gut Microbiota Dysbiosis in Inflammatory Bowel Diseases. Microorganisms. 27. mars 2021;9(4):697.
79. Brown H, Esterházy D. Intestinal immune compartmentalization: implications of tissue specific determinants in health and disease. Mucosal Immunol. november 2021;14(6):1259–70.
80. Mowat AM, Agace WW. Regional specialization within the intestinal immune system. Nat Rev Immunol. oktober 2014;14(10):667–85.
81. Ramanan D, Cadwell K. Intrinsic Defense Mechanisms of the Intestinal Epithelium. Cell Host Microbe. 13. april 2016;19(4):434–41.
82. Tezuka H, Ohteki T. Regulation of IgA Production by Intestinal Dendritic Cells and Related Cells. Front Immunol. 13. august 2019;10:1891.
83. Kumar Bharathkar S, Parker BW, Malyutin AG, Haloi N, Huey-Tubman KE, Tajkhorshid E, mfl. The structures of secretory and dimeric immunoglobulin A. eLife. 27. oktober 2020;9:e56098.
84. Iftekhar A, Sigal M. Defence and adaptation mechanisms of the intestinal epithelium upon infection. Int J Med Microbiol. april 2021;311(3):151486.
85. Yang S, Yu M. Role of Goblet Cells in Intestinal Barrier and Mucosal Immunity. J Inflamm Res. juli 2021;Volume 14:3171–83.
86. Elmore SA. Enhanced histopathology of mucosa-associated lymphoid tissue. Toxicol Pathol. 2006;34(5):687–96.
87. Donaldson DS, Else KJ, Mabbott NA. The Gut-Associated Lymphoid Tissues in the Small Intestine, Not the Large Intestine, Play a Major Role in Oral Prion Disease Pathogenesis. J Virol. september 2015;89(18):9532–47.
88. Műzes G, Bohusné Barta B, Sipos F. Colitis and Colorectal Carcinogenesis: The Focus on Isolated Lymphoid Follicles. Biomedicines. 21. januar 2022;10(2):226.
89. Park JI, Cho SW, Kang JH, Park TE. Intestinal Peyer's Patches: Structure, Function, and In Vitro Modeling. Tissue Eng Regen Med. juni 2023;20(3):341–53.
90. Rezk SA, Nathwani BN, Zhao X, Weiss LM. Follicular dendritic cells: origin, function, and different disease-associated patterns. Hum Pathol. juni 2013;44(6):937–50.
91. Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, mfl. Cancer statistics for the year 2020: An overview. Int J Cancer. 5. april 2021;
92. Chandraprasad MS, Dey A, Swamy MK. Introduction to cancer and treatment approaches. I: Paclitaxel [Internett]. Elsevier; 2022 [sitert 21. april 2024]. s. 1–27. Tilgjengelig på: https://linkinghub.elsevier.com/retrieve/pii/B9780323909518000102
93. Thiagarajan P, Parker CJ, Prchal JT. How Do Red Blood Cells Die? Front Physiol. 2021;12:655393.
94. Park JH, Kotani T, Konno T, Setiawan J, Kitamura Y, Imada S, mfl. Promotion of Intestinal Epithelial Cell Turnover by Commensal Bacteria: Role of Short-Chain Fatty Acids. PloS One. 2016;11(5):e0156334.
95. Vijg J. Somatic mutations, genome mosaicism, cancer and aging. Curr Opin Genet Dev. juni 2014;26:141–9.
96. Labster [Internett]. 5 Ways To Get Students Excited About Medical Genetics. Tilgjengelig på: https://www.labster.com/blog/get-students-excited-medical-genetics
97. Goldberg ML, Hartwell LH, Fischer JA, Hood LE. Genetics: from genes to genomes. Seventh edition. New York, NY: McGraw Hill Education; 2021.
98. Kumari S, Sharma S, Advani D, Khosla A, Kumar P, Ambasta RK. Unboxing the molecular modalities of mutagens in cancer. Environ Sci Pollut Res. september 2022;29(41):62111–59.
99. THE GENETIC CODE [Internett]. Tilgjengelig på: https://slcc.pressbooks.pub/collegebiology1/chapter/the-genetic-code/
100. David Adams. FRAMESHIFT MUTATION [Internett]. Tilgjengelig på: https://www.genome.gov/genetics-glossary/Frameshift-Mutation
101. Phases of the cell cycle [Internett]. Tilgjengelig på: https://www.khanacademy.org/science/ap-biology/cell-communication-and-cell-cycle/cell-cycle/a/cell-cycle-phases
102. Nassour J, Schmidt TT, Karlseder J. Telomeres and Cancer: Resolving the Paradox. Annu Rev Cancer Biol. 4. mars 2021;5(1):59–77.
103. Robert Sanders. Long-sought structure of telomerase paves way for drugs for aging, cancer. Tilgjengelig på: https://news.berkeley.edu/2018/04/25/long-sought-structure-of-telomerase-paves-way-for-drugs-for-aging-cancer
104. Alzahrani SM, Al Doghaither HA, Al-Ghafari AB. General insight into cancer: An overview of colorectal cancer (Review). Mol Clin Oncol. desember 2021;15(6):271.

105. Carcinogens and Teratogens [Internett]. Tilgjengelig på: https://chem.libretexts.org/Bookshelves/Introductory_Chemistry/Chemistry_for_Changing_Times_%28Hill_and_McCreary%29/22%3A_Poisons/22.06%3A_Carcinogens_and_Teratogens
106. Rosendahl Huber A, Van Hoeck A, Van Boxtel R. The Mutagenic Impact of Environmental Exposures in Human Cells and Cancer: Imprints Through Time. Front Genet. 20. oktober 2021;12:760039.
107. Chatterjee N, Walker GC. Mechanisms of DNA damage, repair, and mutagenesis. Environ Mol Mutagen. juni 2017;58(5):235–63.
108. Langie SAS, Koppen G, Desaulniers D, Al-Mulla F, Al-Temaimi R, Amedei A, mfl. Causes of genome instability: the effect of low dose chemical exposures in modern society. Carcinogenesis. juni 2015;36(Suppl 1):S61–88.
109. Zhang QZ, Zhu YP, Rahat MA, Kzhyshkowska J. Editorial: Angiogenesis and tumor metastasis. Front Oncol. 17. januar 2023;12:1129736.
110. Osborne C, Wilson P, Tripathy D. Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications. The Oncologist. 2004;9(4):361–77.
111. Cancer and the Cell Cycle. Tilgjengelig på: https://slcc.pressbooks.pub/collegebiology1/chapter/cancer-and-the-cell-cycle/
112. Zandi R, Larsen AB, Andersen P, Stockhausen MT, Poulsen HS. Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cell Signal. oktober 2007;19(10):2013–23.
113. Han CW, Jeong MS, Jang SB. Structure, signaling and the drug discovery of the Ras oncogene protein. BMB Rep. juli 2017;50(7):355–60.
114. Dang CV. MYC on the path to cancer. Cell. 30. mars 2012;149(1):22–35.
115. American Cancer Society [Internett]. Oncogenes, Tumor Suppressor Genes, and DNA Repair Genes. Tilgjengelig på: https://www.cancer.org/cancer/understanding-cancer/genes-and-cancer/oncogenes-tumor-suppressor-genes.html
116. Park JH, Zhuang J, Li J, Hwang PM. p53 as guardian of the mitochondrial genome. FEBS Lett. april 2016;590(7):924–34.
117. Hamzehloie T, Mojarrad M, Hasanzadeh Nazarabadi M, Shekouhi S. The role of tumor protein 53 mutations in common human cancers and targeting the murine double minute 2-p53 interaction for cancer therapy. Iran J Med Sci. mars 2012;37(1):3–8.
118. Zhang W, Yu Y. The Important Molecular Markers on Chromosome 17 and Their Clinical Impact in Breast Cancer. Int J Mol Sci. 5. september 2011;12(9):5672–83.
119. Cell Cycle and Checkpoint Controls [Internett]. Tilgjengelig på: https://www.ptgcn.com/products/featured-products/cell-cycle-and-checkpoint-controls/
120. Łukasik P, Załuski M, Gutowska I. Cyclin-Dependent Kinases (CDK) and Their Role in Diseases Development–Review. Int J Mol Sci. 13. mars 2021;22(6):2935.
121. Cyclin E [Internett]. Tilgjengelig på: https://en.wikipedia.org/wiki/Cyclin_E
122. Bertoli C, Skotheim JM, De Bruin RAM. Control of cell cycle transcription during G1 and S phases. Nat Rev Mol Cell Biol. august 2013;14(8):518–28.
123. Stewart ZA, Pietenpol JA. p53 Signaling and Cell Cycle Checkpoints. Chem Res Toxicol. 1. mars 2001;14(3):243–63.
124. Foster DA, Yellen P, Xu L, Saqcena M. Regulation of G1 Cell Cycle Progression: Distinguishing the Restriction Point from a Nutrient-Sensing Cell Growth Checkpoint(s). Genes Cancer. november 2010;1(11):1124–31.
125. Chen J, Potlapalli R, Quan H, Chen L, Xie Y, Pouriyeh S, mfl. Exploring DNA Damage and Repair Mechanisms: A Review with Computational Insights. Biotech Basel Switz. 16. januar 2024;13(1):3.
126. Lieber MR. The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. Annu Rev Biochem. 2010;79:181–211.
127. Li C, Liu F, Huang D, Wu Y, Wang Z, Xu Y. The correlation between DNA mismatch repair status and the clinicopathological and molecular features of Chinese sporadic colorectal cancer. Transl Cancer Res. januar 2020;9(1):137–44.
128. Ludovic Bourré. DNA Damage Response (DDR) [Internett]. 2020. Tilgjengelig på: https://blog.crownbio.com/dna-damage-response
129. Pećina-Šlaus N, Kafka A, Salamon I, Bukovac A. Mismatch Repair Pathway, Genome Stability and Cancer. Front Mol Biosci. 26. juni 2020;7:122.
130. Peltomäki P, Nyström M, Mecklin JP, Seppälä TT. Lynch Syndrome Genetics and Clinical Implications. Gastroenterology. april 2023;164(5):783–99.

131. Ferlizza E, Solmi R, Sgarzi M, Ricciardiello L, Lauriola M. The Roadmap of Colorectal Cancer Screening. Cancers. 4. mars 2021;13(5):1101.
132. Newman P, Muscat J. Potential Role of Non-Steroidal Anti-Inflammatory Drugs in Colorectal Cancer Chemoprevention for Inflammatory Bowel Disease: An Umbrella Review. Cancers. 9. februar 2023;15(4):1102.
133. Esther A Torres. Inflammatory bowel disease (IBD) [Internett]. Tilgjengelig på: https://patient.gastro.org/inflammatory-bowel-disease-ibd/
134. O'Callaghan A, van Sinderen D. Bifidobacteria and Their Role as Members of the Human Gut Microbiota. Front Microbiol. 2016;7:925.
135. Hodgkinson K, El Abbar F, Dobranowski P, Manoogian J, Butcher J, Figeys D, mfl. Butyrate's role in human health and the current progress towards its clinical application to treat gastrointestinal disease. Clin Nutr. februar 2023;42(2):61–75.
136. Tariq K, Ghias K. Colorectal cancer carcinogenesis: a review of mechanisms. Cancer Biol Med. mars 2016;13(1):120–35.
137. Lyon (FR): International Agency for Research on Cancer. Colorectal cancer screening. I 2019. Tilgjengelig på: https://www.ncbi.nlm.nih.gov/books/NBK553197/
138. Hasbullah HH, Musa M. Gene Therapy Targeting p53 and KRAS for Colorectal Cancer Treatment: A Myth or the Way Forward? Int J Mol Sci. 3. november 2021;22(21):11941.
139. Testa U, Pelosi E, Castelli G. Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells. Med Sci Basel Switz. 13. april 2018;6(2):31.
140. Genetics of Colorectal Cancer (PDQ®)–Health Professional Version. Tilgjengelig på: https://www.cancer.gov/types/colorectal/hp/colorectal-genetics-pdq#top
141. Abu-Ghazaleh N, Kaushik V, Gorelik A, Jenkins M, Macrae F. Worldwide prevalence of Lynch syndrome in patients with colorectal cancer: Systematic review and meta-analysis. Genet Med. mai 2022;24(5):971–85.
142. Centers for Disease Control and Prevention [Internett]. Lynch Syndrome. Tilgjengelig på: https://www.cdc.gov/genomics/disease/colorectal_cancer/lynch.htm
143. Jiao Q, Ren Y, Ariston Gabrie AN, Wang Q, Wang Y, Du L, mfl. Advances of immune checkpoints in colorectal cancer treatment. Biomed Pharmacother. mars 2020;123:109745.
144. Shussman N, Wexner SD. Colorectal polyps and polyposis syndromes. Gastroenterol Rep. februar 2014;2(1):1–15.
145. Hyun E, Helewa RM, Singh H, Wightman HR, Park J. Serrated polyps and polyposis of the colon: a brief review for surgeon endoscopists. Can J Surg J Can Chir. 2021;64(6):E561–6.
146. Dr. Paul Davis. Colorectal Polyps As Precursors to Colorectal Malignancy [Internett]. Tilgjengelig på: https://www.rgare.com/knowledge-center/article/colorectal-polyps-as-precursors-to-colorectal-malignancy
147. Hossain MS, Karuniawati H, Jairoun AA, Urbi Z, Ooi DJ, John A, mfl. Colorectal Cancer: A Review of Carcinogenesis, Global Epidemiology, Current Challenges, Risk Factors, Preventive and Treatment Strategies. Cancers. 29. mars 2022;14(7):1732.
148. Abed J, Maalouf N, Manson AL, Earl AM, Parhi L, Emgård JEM, mfl. Colon Cancer-Associated Fusobacterium nucleatum May Originate From the Oral Cavity and Reach Colon Tumors via the Circulatory System. Front Cell Infect Microbiol. 2020;10:400.
149. Wu J, Li Q, Fu X. Fusobacterium nucleatum Contributes to the Carcinogenesis of Colorectal Cancer by Inducing Inflammation and Suppressing Host Immunity. Transl Oncol. juni 2019;12(6):846–51.
150. Zhang Y, Wang Y, Zhang B, Li P, Zhao Y. Methods and biomarkers for early detection, prediction, and diagnosis of colorectal cancer. Biomed Pharmacother. juli 2023;163:114786.
151. Meril [Internett]. Colorectal cancer (colon cancer). Tilgjengelig på: https://www.merillife.com/patients-caregivers/general-surgery/colorectal-cancer-colon-cancer
152. Screening Tests to Detect Colorectal Cancer and Polyps [Internett]. Tilgjengelig på: https://www.cancer.gov/types/colorectal/screening-fact-sheet
153. Half E, Bercovich D, Rozen P. Familial adenomatous polyposis. Orphanet J Rare Dis. 12. oktober 2009;4:22.
154. Asad-Ur-Rahman F, Saif MW. Elevated Level of Serum Carcinoembryonic Antigen (CEA) and Search for a Malignancy: A Case Report. Cureus. 20. juni 2016;8(6):e648.
155. Folasade (Fola) Popoola May. Colorectal cancer screening options [Internett]. Tilgjengelig på: https://patient.gastro.org/crcscreening/

156. Ryan D. Rosen; Amit Sapra. TNM Classification [Internett]. Tilgjengelig på: https://www.ncbi.nlm.nih.gov/books/NBK553187/
157. Colorectal Cancer: Stages. Tilgjengelig på: https://www.cancer.net/cancer-types/colorectal-cancer/stages
158. PDQ Adult Treatment Editorial Board. Colon Cancer Treatment (PDQ®): Patient Version. I: PDQ Cancer Information Summaries [Internett]. Bethesda (MD): National Cancer Institute (US); 2002 [sitert 21. april 2024]. Tilgjengelig på: http://www.ncbi.nlm.nih.gov/books/NBK65880/
159. BONE CANCER AND THE SURVIVAL RATE [Internett]. Tilgjengelig på: https://lonniearmstrong4.wordpress.com
160. Kumar A, Gautam V, Sandhu A, Rawat K, Sharma A, Saha L. Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review. World J Gastrointest Surg. 27. april 2023;15(4):495–519.
161. Treatment of Colon Cancer, by Stage [Internett]. Tilgjengelig på: https://www.cancer.org/cancer/types/colon-rectal-cancer/treating/by-stage-colon.html
162. GLOBAL COLON CANCER ASSOCIATION [Internett]. Chemotherapy for Colorectal Cancer. Tilgjengelig på: https://www.globalcca.org/learn/colorectal-cancer-chemotherapy
163. World Health Organization [Internett]. Colorectal cancer. Tilgjengelig på: https://www.who.int/news-room/fact-sheets/detail/colorectal-cancer
164. American Cancer Society [Internett]. 2024. Targeted Therapy Drugs for Colorectal Cancer. Tilgjengelig på: https://www.cancer.org/cancer/types/colon-rectal-cancer/treating/targeted-therapy.html
165. Jafari M, Laraqui A, Baba W, Benmokhtar S, Zaitouni SE, Ali AA, mfl. Prevalence and patterns of mutations in RAS/RAF/MEK/ERK/MAPK signaling pathway in colorectal cancer in North Africa. BMC Cancer. 7. november 2022;22(1):1142.
166. Degirmenci U, Wang M, Hu J. Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy. Cells. 13. januar 2020;9(1):198.
167. Koveitypour Z, Panahi F, Vakilian M, Peymani M, Seyed Forootan F, Nasr Esfahani MH, mfl. Signaling pathways involved in colorectal cancer progression. Cell Biosci. desember 2019;9(1):97.
168. Wang Q, Shen X, Chen G, Du J. Drug Resistance in Colorectal Cancer: From Mechanism to Clinic. Cancers. 14. juni 2022;14(12):2928.
169. Chen N, He L, Zou Q, Deng H. HER2 targeted therapy in colorectal Cancer: Current landscape and future directions. Biochem Pharmacol. mai 2024;223:116101.
170. Ivanova M, Venetis K, Guerini-Rocco E, Bottiglieri L, Mastropasqua MG, Garrone O, mfl. HER2 in Metastatic Colorectal Cancer: Pathology, Somatic Alterations, and Perspectives for Novel Therapeutic Schemes. Life. 9. september 2022;12(9):1403.
171. Casak SJ, Horiba MN, Yuan M, Cheng J, Lemery SJ, Shen YL, mfl. FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, HER2-Positive RAS Wild-Type Colorectal Cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 1. november 2023;29(21):4326–30.
172. Sharon Reynolds. Tucatinib and Trastuzumab Combination Approved for Advanced Colorectal Cancer [Internett]. Tilgjengelig på: https://www.cancer.gov/news-events/cancer-currents-blog/2023/fda-tucatinib-her2-colorectal-cancer
173. NATIONAL CANCER INSTITUTE [Internett]. Immunotherapy to Treat Cancer. Tilgjengelig på: https://www.cancer.gov/about-cancer/treatment/types/immunotherapy
174. American Cancer Society [Internett]. Immunotherapy for Colorectal Cancer. Tilgjengelig på: https://www.cancer.org/cancer/types/colon-rectal-cancer/treating/immunotherapy.html
175. GLOBAL COLON CANCER ASSOCIATION [Internett]. Immunotherapy for Colorectal Cancer. Tilgjengelig på: https://www.globalcca.org/learn/colorectal-cancer-immunotherapy
176. Ganesh K, Stadler ZK, Cercek A, Mendelsohn RB, Shia J, Segal NH, mfl. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. juni 2019;16(6):361–75.
177. Zabeti Touchaei A, Vahidi S. MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways. Cancer Cell Int. 10. mars 2024;24(1):102.
178. Chen X, Chen LJ, Peng XF, Deng L, Wang Y, Li JJ, mfl. Anti-PD-1/PD-L1 therapy for colorectal cancer: Clinical implications and future considerations. Transl Oncol. februar 2024;40:101851.
179. Angulo-Aguado M, Orjuela-Amarillo S, Mora-Jácome JF, Córdoba LP, Gallego-Ortiz A, Gaviria-Sabogal CC, mfl. Functional analysis of CTLA4 promoter variant and its possible implication in colorectal

cancer immunotherapy. Front Med. 3. august 2023;10:1160368.
180. NATIONAL CANCER INSTITUTE [Internett]. CTLA-4. Tilgjengelig på: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/ctla-4
181. Ruff SM, Shannon AH, Pawlik TM. The Role of Targeted Therapy in the Multi-Disciplinary Approach to Colorectal Liver Metastasis. Cancers. 6. juli 2023;15(13):3513.
182. Ghazi B, El Ghanmi A, Kandoussi S, Ghouzlani A, Badou A. CAR T-cells for colorectal cancer immunotherapy: Ready to go? Front Immunol. 2022;13:978195.
183. Sur D, Havasi A, Cainap C, Samasca G, Burz C, Balacescu O, mfl. Chimeric Antigen Receptor T-Cell Therapy for Colorectal Cancer. J Clin Med. 9. januar 2020;9(1):182.
184. Dagar G, Gupta A, Masoodi T, Nisar S, Merhi M, Hashem S, mfl. Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments. J Transl Med. 7. juli 2023;21(1):449.
185. Aparicio C, Belver M, Enríquez L, Espeso F, Núñez L, Sánchez A, mfl. Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells. Int J Mol Sci. 29. oktober 2021;22(21):11781.
186. Srivastava AK, Guadagnin G, Cappello P, Novelli F. Post-Translational Modifications in Tumor-Associated Antigens as a Platform for Novel Immuno-Oncology Therapies. Cancers. 26. desember 2022;15(1):138.
187. Kamrani A, Nasiri H, Hassanzadeh A, Ahmadian Heris J, Mohammadinasab R, Sadeghvand S, mfl. New immunotherapy approaches for colorectal cancer: focusing on CAR-T cell, BiTE, and oncolytic viruses. Cell Commun Signal. 19. januar 2024;22(1):56.